

# Table of Contents

## **PART I. OPERATIONAL ISSUES FOR HEALTH CARE FACILITIES**

### **CHAPTER 1. INTRODUCTION TO HEALTH LAW**

#### **I. WHAT IS HEALTH LAW?**

§ 1:1 Generally

#### **II. CURRENT TRENDS IN THE HEALTH CARE INDUSTRY**

§ 1:2 Generally

§ 1:3 Information technology

§ 1:4 Renewed focus on public health

§ 1:5 Pharmaceuticals

§ 1:6 Medical errors

#### **III. ADMINISTRATIVE LAW: THE BASICS**

§ 1:7 Generally

#### **IV. LICENSURE/CREDENTIALS**

§ 1:8 Generally

§ 1:9 State approval to provide health care services

§ 1:10 Federal oversight of professional credentialing and  
disciplinary activity

§ 1:11 Accreditation and certification

#### **V. PATIENT CARE AND TREATMENT**

§ 1:12 Negligence

§ 1:13 Informed consent of patient

§ 1:14 Right to refuse treatment

§ 1:15 Privacy of health care information

#### **VI. PAYMENT FOR HEALTH CARE SERVICES**

§ 1:16 Third-party payment arrangements

§ 1:17 Government payment programs—Medicare and  
Medicaid

**VII. FRAUD AND ABUSE**

§ 1:18 Generally

**VIII. TAX-EXEMPT ORGANIZATIONS AND  
NONPROFIT STATUS**

§ 1:19 Generally

**IX. ANTITRUST**

§ 1:20 Generally

**CHAPTER 1A. THE FUNDAMENTALS OF  
PUBLIC HEALTH LAW**

**I. INTRODUCTION**

§ 1A:1 Generally

**II. GOVERNMENT STRUCTURE, PUBLIC HEALTH  
INFRASTRUCTURE, AND LEGAL  
PREPAREDNESS**

§ 1A:2 Basic government structure

§ 1A:3 Basic public health infrastructure

§ 1A:4 Legal preparedness

**III. FUNDAMENTAL AND DEVELOPING AREAS OF  
PUBLIC HEALTH LAW**

§ 1A:5 Public health basics

§ 1A:6 Public health law basics

§ 1A:7 Developing areas of public health law

**IV. ADVANCING HEALTH OUTCOMES AND  
EQUITY BY COMPLYING WITH PUBLIC  
HEALTH LAWS**

§ 1A:8 Generally

**V. CHANGES IN PUBLIC HEALTH AUTHORITY  
SINCE COVID-19**

§ 1A:9 Generally

**VI. CONCLUSION**

§ 1A:10 Generally

TABLE OF CONTENTS

**CHAPTER 1B. FEDERAL PREEMPTION OF STATE HEALTH CARE REGULATION**

- § 1B:1 Introduction
- § 1B:2 Overview of key legal authorities and cases:  
Federalism’s tug of war with the Tenth Amendment and the supremacy clause
- § 1B:3 Tenth Amendment and Federalism
- § 1B:4 Federalism’s relationship with public health
- § 1B:5 Quarantine and steamships: First legal authorities for state health care regulation
- § 1B:6 *Jacobson v. Commonwealth of Massachusetts* (1905): Cornerstone to states’ right to regulate health care
- § 1B:7 Limits to Federalism
- § 1B:8 The challenge to the Tenth: Strong federal government and the supremacy clause
- § 1B:9 “Voldemort of health law”: ERISA preempts Federalism
- § 1B:10 The statutory test for ERISA preemption
- § 1B:11 The judicial test for ERISA preemption
- § 1B:12 The current environment: Recent developments on states’ ability to regulate health care
- § 1B:13 Case study: ERISA preemption of state health care regulation
- § 1B:14 Regulation of hospital costs not preempted
- § 1B:15 Taxation of hospitals not preempted
- § 1B:16 State HMO Act not preempted
- § 1B:17 Any willing provider statutes not preempted
- § 1B:18 All payer claims databases are preempted
- § 1B:19 *Rutledge v. Pharmaceutical Care Management Association* (2020) clarifies the Supreme Court’s ERISA jurisprudence
- § 1B:20 Case study: COVID-19’s reckoning on *Jacobson* deference
- § 1B:21 The COVID-19 shift of the supreme Court’s *Jacobson* jurisprudence
- § 1B:22 The split among Circuit Courts on COVID-19 and *Jacobson*
- § 1B:23 Conclusion

**CHAPTER 2. MEDICAL STAFF AND HOSPITALS: LEGAL AND BUSINESS ISSUES**

- § 2:1 Introduction
- § 2:2 Corporate negligence
- § 2:3 Medical staff bylaws as a contract
- § 2:4 Compliance with bylaws
- § 2:5 Antitrust concerns

- § 2:6 Restraint of trade
- § 2:7 Peer review as “state mandated” action
- § 2:8 Economic credentialing
- § 2:9 Exclusive contracts
- § 2:10 Board certification
- § 2:11 Geographic proximity requirements
- § 2:12 Number of admissions
- § 2:13 On-call coverage issues
- § 2:14 Health care entity/physician integration issues
- § 2:15 Reasons for integration
- § 2:16 Application of employment policies and procedures
- § 2:17 Potential claims of employed and nonemployed medical staff members
- § 2:18 Heightened risk of discrimination claims
- § 2:19 Professional liability insurance considerations
- § 2:20 Coordination of employment agreement and medical staff bylaw language
- § 2:21 Impact of acos and clinically integrated networks on medical staff credentialing
- § 2:22 Hospitalists, intensivists, and other hospital-based physicians
- § 2:23 Vicarious liability
- § 2:24 Reimbursement for hospital-based physician services
- § 2:25 Compensation for hospital-based physician services
- § 2:26 Hospitalists
- § 2:27 Development of medical staff categories without treatment privileges
- § 2:28 Responding to credentialing inquiries

## **CHAPTER 2A. PEER REVIEW AND CREDENTIALING**

- § 2A:1 Introduction
- § 2A:2 Practitioner credentialing and peer review
- § 2A:3 Federal law on credentialing and peer review
- § 2A:4 The Health Care Quality Improvement Act of 1986
- § 2A:5 The impetus for the enactment of HCQIA
- § 2A:6 Overview of HCQIA’s immunity provisions and reporting requirements
- § 2A:7 The national practitioner data bank
- § 2A:8 The effect of the Americans with Disabilities Act on current credentialing practices
- § 2A:9 Overview of the ADA
- § 2A:10 Impact of the ADA on current credentialing practices
- § 2A:11 The effect of Section 504 of the Rehabilitation Act of 1973
- § 2A:12 State law on credentialing
- § 2A:13 Accreditation standards

## TABLE OF CONTENTS

§ 2A:14	Internet credentialing
§ 2A:15	Credentialing aging physicians
§ 2A:16	Credentialing employed practitioners
§ 2A:17	Documentation of credentialing criteria
§ 2A:18	New health care entities and impact on peer review and credentialing
§ 2A:19	Accountable care organization credentialing
§ 2A:20	Non-physician practitioners and medical staff membership
§ 2A:21	Combined medical staffs
§ 2A:22	Retail clinics
§ 2A:23	Avoiding liability risks related to credentialing
§ 2A:24	Negligent credentialing
§ 2A:25	Economic credentialing
§ 2A:26	Disclosure of individual providers' quality outcome information
§ 2A:27	Violation of the ADA or the Rehabilitation Act
§ 2A:28	Information sharing and contractual allocation of risk
§ 2A:29	Contractual provisions for the confidentiality of information
§ 2A:30	Obtaining appropriate releases
§ 2A:31	Negligent referrals: Lessons from the <i>Kadlec</i> case
§ 2A:32	Risks in the credentialing and peer-review process
§ 2A:33	Responding to identified risks
§ 2A:34	Conclusion

## CHAPTER 3. MEDICAL STAFF BYLAWS

§ 3:1	Introduction
§ 3:2	Avoiding unnecessary processing of applications
§ 3:3	Dealing with incomplete applications
§ 3:4	Avoiding unnecessary hearings
§ 3:5	Service on-call rosters
§ 3:6	Waiver of bylaw and other requirements
§ 3:7	Responsibilities of medical staff membership
§ 3:8	Summary action
§ 3:9	Attorney representation
§ 3:10	Hearing provisions
§ 3:11	Consideration of hearing panel report and recommendations by medical executive committee
§ 3:12	Peer review recommendations
§ 3:13	Obligation to pay attorney fees
§ 3:14	Chief of staff duties
§ 3:15	Medical staff committees
§ 3:16	Confidentiality
§ 3:17	Amendment of bylaws

## **CHAPTER 3A. MEDICAL STAFF PEER REVIEW HEARINGS**

### **I. INTRODUCTION**

§ 3A:1 Introduction

### **II. HEALTH CARE QUALITY IMPROVEMENT ACT OF 1986**

§ 3A:2 Health Care Quality Improvement Act of 1986

§ 3A:3 When is A Hearing Required?

§ 3A:4 Considerations for Pre-Hearing and Hearing Conduct

### **III. MEDICAL STAFF BYLAWS: THE FRAMEWORK FOR EFFECTIVE HEARING PROCEDURES**

§ 3A:5 Variations in Select Bylaws Provisions

§ 3A:6 Presumption of Compliance

### **IV. WITNESSES AND EVIDENCE REQUIREMENTS AND STRATEGY**

§ 3A:7 Understanding How Peer Review Proceedings Differ  
From General Litigation.

§ 3A:8 Disclosures and Production

§ 3A:9 Scheduling Orders

§ 3A:10 Narrowing of Substantive Issues and Facts

§ 3A:11 Witnesses, Exhibits, and the Pre-Hearing Conference  
Order

### **V. PROBLEMATIC ISSUES**

§ 3A:12 Objections Strategy

§ 3A:13 Non-compliance With Hearing Officer Rulings;  
Argumentative Counsel

§ 3A:14 The Unavailable Witness

§ 3A:15 Questions By The Hearing Panel

### **VI. DEALING WITH SURPRISES**

§ 3A:16 New Adverse Action

§ 3A:17 Panel Member Absence

§ 3A:18 Last-Minute Adjournment Requests

§ 3A:19 Litigation

TABLE OF CONTENTS

**CHAPTER 3B. ADVANCED PRACTICE PROVIDERS\***

**I. INTRODUCTION**

§ 3B:1 What are Advanced Practice Providers (APPs)

**II. NAVIGATING REGULATORY REQUIREMENTS**

§ 3B:2 Advanced Practice Providers Care Delivery Models

§ 3B:3 Obtaining state licensure—APRN compact states

§ 3B:4 —PA compact states

§ 3B:5 Key differing state-based requirements

§ 3B:6 Limits on the number of APPs a physician can supervise

§ 3B:7 Back-up supervising physician requirement

§ 3B:8 Other varying state-based issues/checklist

§ 3B:9 Medicare “Operational” Requirements

**III. CONCLUSION**

§ 3B:10 Current and Future Trends

**CHAPTER 4. STATE MEDICAL RECORDS LAW**

§ 4:1 Introduction

§ 4:2 Medical Record Content Requirements

§ 4:3 Medicare Conditions of Participation

§ 4:4 State Laws Governing Medical Record Content

§ 4:5 Accreditation Standards

**I. RETENTION OF MEDICAL RECORDS**

§ 4:6 Mandatory Retention Periods under State Law

§ 4:7 Statutes of Limitation

§ 4:8 Liability For Failure To Retain Medical Records

§ 4:9 Storage Requirements for Medical Records

§ 4:10 Destruction of Medical Records

§ 4:11 Ownership of Medical Records

§ 4:12 State Laws Governing Privacy and Confidentiality

§ 4:13 Duty of Confidentiality

§ 4:14 Right of Access

§ 4:15 Disclosure

**CHAPTER 4A. HEALTH INFORMATION TECHNOLOGY (HEALTH IT)**

**I. INTRODUCTION TO HEALTH IT**

§ 4A:1 Generally

## **II. HEALTH IT APPLICATIONS AND USES**

- § 4A:2 Electronic health records
- § 4A:3 Physician practice tools
- § 4A:4 Health information exchange
- § 4A:5 Clinical decision support
- § 4A:6 Rapid learning health systems
- § 4A:7 Artificial intelligence, cognitive computing and natural language processing
- § 4A:8 Application programming interfaces interaction with patient applications and devices
- § 4A:9 Telemedicine
- § 4A:10 Cloud computing

## **III. DIGITAL HEALTH VALUE PROPOSITION**

- § 4A:11 Generally

## **IV. UNIQUE LEGAL AND REGULATORY CONSIDERATIONS APPLICABLE TO HEALTH IT**

- § 4A:12 Generally

## **V. MEDICARE AND MEDICAID EHR INCENTIVE PROGRAM**

- § 4A:13 Program basics
- § 4A:14 Medicare EHR incentive program
- § 4A:15 Medicaid EHR incentive program
- § 4A:16 MACRA

## **VI. CERTIFICATION PROGRAM**

- § 4A:17 Generally
- § 4A:18 Who must obtain certification
- § 4A:19 Testing labs and certifying bodies
- § 4A:20 Certification criteria

## **VII. PATIENT SAFETY**

- § 4A:21 FDA regulation of health IT
- § 4A:22 Patient safety organizations and health IT

## **VIII. INFORMATION PRIVACY AND SECURITY**

- § 4A:23 HIPAA and health IT developers
- § 4A:24 Security risk assessments
- § 4A:25 Service organization controls audits
- § 4A:26 Third party certifications (HITRUST)

TABLE OF CONTENTS

- § 4A:27 Patient access to electronic records
- § 4A:28 Laws applicable to sensitive health information
- § 4A:29 Consent for participation in HIE
- § 4A:30 Accounting of disclosures
- § 4A:31 De-identification of PHI

**IX. INTELLECTUAL PROPERTY  
CONSIDERATIONS**

- § 4A:32 Generally
- § 4A:33 Patents
- § 4A:34 Copyrights
- § 4A:35 Trade secrets
- § 4A:36 Trademarks

**X. OWNERSHIP AND LICENSING OF HEALTH IT  
DATA**

- § 4A:37 Generally

**XI. PLANNING, DUE DILIGENCE, AND  
CONTRACTING CONSIDERATIONS**

- § 4A:38 Generally
- § 4A:39 Technology system features, functions and performance capabilities
- § 4A:40 Scope of license

**XII. IMPLEMENTATION**

- § 4A:41 Implementation plan
- § 4A:42 Implementation fees
- § 4A:43 Acceptance testing
- § 4A:44 Maintenance and support

**XIII. GENERAL ACCOUNTABILITY AND  
COOPERATION**

- § 4A:45 Generally
- § 4A:46 Data integrity—Accuracy, completeness and availability
- § 4A:47 Information blocking
- § 4A:48 Disaster recovery and business continuity

**XIV. COMPLIANCE CAPABILITIES**

- § 4A:49 Generally

**XV. WARRANTIES**

- § 4A:50 Generally

- § 4A:51 Product warranty
- § 4A:52 Uptime and response time commitments
- § 4A:53 Professional services warranty
- § 4A:54 Malicious code

## **XVI. INDEMNIFICATION**

- § 4A:55 Generally
- § 4A:56 Intellectual property infringement indemnification
- § 4A:57 Data breach liability indemnification
- § 4A:58 Other indemnification

## **XVII. TERM AND TERMINATION**

- § 4A:59 Generally
- § 4A:60 Transition and migration

## **XVIII. LIMITATIONS AND DISCLAIMERS OF LIABILITY**

- § 4A:61 Generally
- § 4A:62 Malpractice/misuse disclaimer
- § 4A:63 Indemnification for data breach liability
- § 4A:64 Other indemnification obligations

## **XIX. DISPUTE RESOLUTION**

- § 4A:65 Generally

## **XX. SPECIAL CONSIDERATIONS IN CLOUD COMPUTING AGREEMENTS**

- § 4A:66 Generally
- § 4A:67 Multi-tenant cloud: sharing of infrastructure v. segregation of data
- § 4A:68 Disaster recovery and business continuity plans
- § 4A:69 Cross-border concerns

Appendix A. *[Reserved]*

Appendix B. *[Reserved]*

Appendix C. Overview of 2015 Edition CEHRT Criteria for Medicare EHR Incentive Program Meaningful Use Program

Appendix D. Overview of HIPAA Security Assessment Requirements

## **CHAPTER 4B. HEALTH INFORMATION TECHNOLOGY: CONTRACTING BASICS**

- § 4B:1 Introduction

## TABLE OF CONTENTS

- § 4B:2 Problems arising in HIT projects
- § 4B:3 Terminology

### **I. CONTRACTING ISSUES**

- § 4B:4 Scope and pricing of licensed rights to use software
- § 4B:5 Counseling regarding integration clauses
- § 4B:6 Functionality
- § 4B:7 Right to use customer data
- § 4B:8 Implementation and testing
- § 4B:9 HIT-related vendor warranties
- § 4B:10 General IT warranties
- § 4B:11 Remedies and transition assistance

## **CHAPTER 5. HEALTH INFORMATION PRIVACY AND SECURITY LAWS**

### **I. PRIVACY**

- § 5:1 Overview of Federal Privacy Law
- § 5:2 Scope of the Federal Privacy Rule
- § 5:3 —Covered entity
- § 5:4 —Business associates
- § 5:5 —De-identification
- § 5:6 Permitted uses and disclosures
- § 5:7 —Disclosures to the individual
- § 5:8 —Use and disclosures for treatment, payment, and health care operations
- § 5:9 —Authorizations
- § 5:10 —Opportunity to agree or object
- § 5:11 —Uses and disclosures for which neither authorization nor opportunity to agree or object is required
- § 5:12 —“Minimum necessary” standard
- § 5:13 —A special use and disclosure category: marketing, fundraising, and remunerated treatment communications
- § 5:14 Individual rights under the Privacy Rules
- § 5:15 —Notice
- § 5:16 —Access, amendment, and accounting
- § 5:17 —Right to request additional protection of PHI
- § 5:18 —Psychotherapy notes
- § 5:19 —Right to complain
- § 5:20 Business associates
- § 5:21 Limited data sets and data use agreements
- § 5:22 Breach notification
- § 5:23 —Notice to the individual
- § 5:24 —Notice to the media

- § 5:25 —Notice to OCR
- § 5:26 —Notice by a business associate
- § 5:27 Interaction of the Privacy Rules with State and other  
Federal Laws and Regulations—State laws
- § 5:28 —Other Federal Laws
- § 5:29 Compliance dates
- § 5:30 HIPAA enforcement—The HIPAA Enforcement Rule
- § 5:31 —OCR Enforcement practices
- § 5:32 —State attorney general enforcement of privacy rights,  
including HIPAA
- § 5:33 Conclusion

## II. SECURITY

- § 5:34 Overview of security risks
- § 5:35 Specific security threats in health care
- § 5:36 Understanding the cybersecurity risk framework
- § 5:37 Core
- § 5:38 Tiers
- § 5:39 Profiles
- § 5:40 Security of electronic information
- § 5:41 —HIPAA Security Rule
- § 5:42 Risk analysis and risk management
- § 5:43 Access
- § 5:44 —Administrative standards
- § 5:45 —Physical safeguards
- § 5:46 —Technical safeguards
- § 5:47 Authentication
- § 5:48 —Administrative standards—Security awareness and  
training
- § 5:49 —Physical safeguards
- § 5:50 —Technical safeguards
- § 5:51 Integrity
- § 5:52 —Administrative safeguards—Protection from  
malicious software
- § 5:53 —Technical safeguards
- § 5:54 Availability
- § 5:55 —Administrative safeguards
- § 5:56 —Physical safeguards—Facility access control
- § 5:57 —Technical safeguards—Access control
- § 5:58 Business operations
- § 5:59 Enforcement
- § 5:60 Patient access to ePHI
- § 5:61 Operationalizing the Security Rule
- § 5:62 Additional regulators
- § 5:63 Conclusion

TABLE OF CONTENTS

**CHAPTER 5A. PRIVACY ISSUES IN ‘BIG DATA’ ARRANGEMENTS**

**I. INTRODUCTION**

§ 5A:1 Overview

**II. HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT**

§ 5A:2 Use and disclosure of PHI for treatment, payment or health care operations

§ 5A:3 Use and disclosure of PHI for research

**III. APPLICATION OF HIPAA PRIVACY RULES TO BIG DATA ARRANGEMENTS**

§ 5A:4 De-identified data

§ 5A:5 Limited Data Sets

§ 5A:6 Prohibition on the sale of PHI without written authorization

§ 5A:7 Minimum necessary standard

**IV. FEDERAL CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS**

§ 5A:8 Applicability of the Part 2 Regulations’ disclosure restrictions

§ 5A:9 The 42 C.F.R. Part 2 Consent Requirements

§ 5A:10 Exceptions to the Part 2 Consent Requirements

**V. COMPLIANCE WITH THE COMMON RULE**

§ 5A:11 Applicability of the common rule and the identifiability standard

§ 5A:12 The HIPAA exemption

**CHAPTER 5B. ANATOMY OF A DATA BREACH**

**I. INTRODUCTION**

§ 5B:1 Introduction

§ 5B:2 Exposure

**II. BEFORE A BREACH OCCURS**

§ 5B:3 Introduction

§ 5B:4 Identify Your “Crown Jewels”

- § 5B:5 Have an actionable plan in place before an intrusion occurs
- § 5B:6 Have appropriate technology and services in place
- § 5B:7 Have appropriate authorization in place to permit network monitoring
- § 5B:8 Ensure legal counsel is familiar with technology and cyber incident management to reduce response time during an incident
- § 5B:9 Ensure organization policies align with your cyber incident response plan
- § 5B:10 Engage with law enforcement before an incident
- § 5B:11 Establish relationships with cyber information sharing organizations

### **III. DURING A BREACH**

- § 5B:12 Introduction
- § 5B:13 Steps for managing a breach
- § 5B:14 NSIT voluntary cybersecurity framework

### **IV. GOVERNMENT ENFORCEMENT AFTER A BREACH**

- § 5B:15 OCR enforcement
- § 5B:16 FTC enforcement
- § 5B:17 Litigation risks

### **V. CONCLUSION**

- § 5B:18 Conclusion

## **CHAPTER 5C. INFORMATION BLOCKING**

- § 5C:1 Introduction

### **I. SECTION 4004 OF THE 21ST CENTURY CURES ACT—INFORMATION BLOCKING**

- § 5C:2 Background
- § 5C:3 Guidance and construction
- § 5C:4 Enforcement procedures and penalties

### **II. PROPOSED RULES**

- § 5C:5 ONC proposed rules
- § 5C:6 CMS proposed rule

### **III. FINAL INTEROPERABILITY RULES**

- § 5C:7 Highlights of the Final Rules

TABLE OF CONTENTS

**IV. RELATION OF INFORMATION BLOCKING TO PROPOSED ANTI-KICKBACK AND STARK STATUTE CHANGES**

- § 5C:8 Proposed changes to Stark Law exceptions
- § 5C:9 Proposed changes to safe harbors under the Anti-Kickback Statute
- § 5C:10 ONC examples of information blocking
- § 5C:11 Conclusion

**CHAPTER 6. LABOR AND EMPLOYMENT**

**I. INTRODUCTION**

- § 6:1 Overview

**II. EMPLOYMENT-AT-WILL**

- § 6:2 Defining the doctrine
- § 6:3 Exceptions to employment-at-will
- § 6:4 Contract
- § 6:5 Public policy and “whistleblowing”
- § 6:6 Protected classifications

**III. BASIC FEDERAL DISCRIMINATION, HARASSMENT, AND ACCOMMODATION LAWS**

- § 6:7 Title VII (42 U.S.C. §§ 2000e *et seq.*)
- § 6:8 The Age Discrimination in Employment Act (29 U.S.C. §§ 621 *et seq.*)
- § 6:9 The Americans with Disabilities Act (42 U.S.C. §§ 12101 *et seq.*)

**IV. THE FAMILY AND MEDICAL LEAVE ACT (29 U.S.C. §§ 2601 *ET SEQ.*)**

- § 6:10 Overview of FMLA

**V. WAGE AND HOUR COMPLIANCE AND COLLECTIVE/CLASS ACTION LITIGATION AMONG HEALTH CARE EMPLOYERS**

- § 6:11 The Fair Labor Standards Act (29 U.S.C. §§ 201 *et seq.*)
- § 6:12 Rise in collective/class action litigation in the health care industry

**VI. NON-COMPETES IN HEALTH CARE**

- § 6:13 Overview of non-competes

**VII. THE INTERSECTION OF LABOR AND EMPLOYMENT LAW WITH MEDICAL STAFF, CREDENTIALING, AND PEER REVIEW**

- § 6:14 Overview
- § 6:15 Staff physicians viewed as employees by the courts
- § 6:16 Hospital's peer review process may create unintended employment relationship
- § 6:17 Production of peer review documents in employment cases

**VIII. COVID-19 MANDATORY VACCINATION PROGRAMS**

- § 6:18 Overview of mandatory COVID-19 vaccination programs
- § 6:19 CMS COVID-19 vaccination rule
- § 6:20 Vaccine mandate exemption requests: medical contraindications, disability accommodation and religious accommodation

**IX. PERFORMANCE MANAGEMENT AND REDUCING THE RISK OF EMPLOYMENT LITIGATION**

- § 6:21 Overview of performance management
- § 6:22 Reasons for termination
- § 6:23 Pre-termination documentation
- § 6:24 Progressive discipline systems
- § 6:25 Investigation of misconduct
- § 6:26 Handling the termination
- § 6:27 Releases

**X. AN INTRODUCTION TO TRADITIONAL LABOR LAW IN HEALTHCARE**

- § 6:28 Overview of traditional labor laws
- § 6:29 National Labor Relations Act (29 U.S.C. §§ 151-169)
- § 6:30 National Labor Relations Board
- § 6:31 Union elections

**CHAPTER 6A. SEXUAL MISCONDUCT IN HEALTH CARE**

**I. OVERVIEW**

- § 6A:1 Introduction
- § 6A:2 Sexual misconduct in health care: What does it look like?

TABLE OF CONTENTS

**II. HEALTH CARE PROVIDERS' REPORTING OBLIGATIONS TO STATE AGENCIES**

- § 6A:3 Introduction
- § 6A:4 Mandatory reporting laws
- § 6A:5 Reporting allegations of sexual misconduct
- § 6A:6 Health care providers' legal exposures for failing to report sexual misconduct

**III. ACADEMIC MEDICAL CENTERS AND THEIR ADDITIONAL OBLIGATIONS TO INVESTIGATE SEXUAL ASSAULT/SEXUAL HARASSMENT AND OTHER CONDUCT UNDER TITLE IX**

- § 6A:7 Introduction
- § 6A:8 Recipients of federal funding
- § 6A:9 Education programs and activities covered by Title IX
- § 6A:10 Individuals protected by Title IX
- § 6A:11 Compliance with Title IX
- § 6A:12 Investigations, interim steps and adjudications
- § 6A:13 Due process

**IV. STRATEGIES FOR COUNSEL AND HEALTH CARE PROVIDERS/INSTITUTIONS FOR RESPONDING TO ALLEGATIONS OF SEXUAL MISCONDUCT IN VARIOUS SETTINGS**

- § 6A:14 Introduction
- § 6A:15 The health care provider
- § 6A:16 Steps counsel for the providers should take
- § 6A:17 The health system/hospital/ambulatory surgical center
- § 6A:18 Steps counsel for the hospital should take
- § 6A:19 Physician practices
- § 6A:20 Academic medical centers
- § 6A:21 Steps counsel for the academic medical center should take

**CHAPTER 6B. EMPLOYING FOREIGN NATIONALS**

**I. INTRODUCTION**

- § 6B:1 Generally

**II. TRENDS IN RECRUITMENT AND RETENTION**

- § 6B:2 Generally

- § 6B:3 Federal agencies with jurisdiction over immigration-related matters
- § 6B:4 Consequences of non-compliance with immigration laws/employers
- § 6B:5 Consequences of non-compliance with immigration laws/employers/foreign nationals
- § 6B:6 Recruitment and retention compliance tips

### **III. IMMIGRATION REFORM UNDER THE TRUMP ADMINISTRATION**

- § 6B:7 Generally
- § 6B:8 Border and Interior Security Enforcement Executive Orders
- § 6B:9 Crime and public safety executive orders
- § 6B:10 “The travel ban” executive orders
- § 6B:11 “Buy American and Hire American” Executive Order No. 13788
- § 6B:12 Other actions

### **IV. NON-IMMIGRANT VISA OPTIONS**

- § 6B:13 Non-immigrant categories and requirements
- § 6B:14 The visa application process

### **V. NON-IMMIGRANT VISA OPTIONS FOR IMGs**

- § 6B:15 Visa options for international medical graduates
- § 6B:16 The H-1B non-immigrant visa class
- § 6B:17 The J-1 non-immigrant visa class and J-1 waivers

### **VI. LEGAL PERMANENT RESIDENCE OPTIONS AND STRATEGIES**

- § 6B:18 Legal permanent residence, aka the “green card”
- § 6B:19 Family-based immigration options
- § 6B:20 Diversity visa lottery
- § 6B:21 Employment-based categories
- § 6B:22 The green card application process

### **VII. U.S. CITIZENSHIP**

- § 6B:23 Generally

### **VIII. CONCLUSION**

- § 6B:24 Generally

## **CHAPTER 6C. WORKPLACE VIOLENCE**

- § 6C:1 Introduction

TABLE OF CONTENTS

- § 6C:2 Historical background
- § 6C:3 Types of workplace violence
- § 6C:4 Sources of workplace violence
- § 6C:5 Practical prevention policies
- § 6C:6 Options for defusing aggression
- § 6C:7 Legal responses to threats and workplace violence events
- § 6C:8 Conclusion

**CHAPTER 7. CLINICAL RESEARCH REGULATIONS**

**I. INTRODUCTION**

- § 7:1 Introduction

**II. NATIONAL RESEARCH ACT/THE BELMONT REPORT**

- § 7:2 National Research Act/The Belmont Report

**III. FEDERAL POLICY/PRE-2018 REQUIREMENTS**

- § 7:3 Federal policy/pre-2018 requirements

**IV. DEPARTMENT OF HEALTH AND HUMAN SERVICES REGULATIONS**

- § 7:4 Department of health and human services regulations
- § 7:5 Institutional assurances
- § 7:6 HHS exempt research

**V. HHS ENFORCEMENT**

- § 7:7 Authority
- § 7:8 For-cause evaluations
- § 7:9 Not-for-cause evaluations
- § 7:10 Post-evaluations procedures

**VI. FOOD AND DRUG ADMINISTRATION (FDA)**

- § 7:11 Role of the FDA
- § 7:12 FDA exempt research
- § 7:13 FDA enforcement

**VII. DISTINCTIONS BETWEEN HHS AND FDA REGULATIONS**

- § 7:14 Distinctions between HHS and FDA regulations

## **VIII. STATE REGULATION**

§ 7:15 State regulation

## **CHAPTER 8. RESEARCH COMPLIANCE**

§ 8:1 Introduction

§ 8:2 Requirements regarding grants, contracts, and finances

§ 8:3 Requirements regarding research subjects

§ 8:4 Compliance plan and administration

§ 8:5 Conclusion

## **CHAPTER 8A. THE COMMERCIALIZATION OF RESEARCH BY ACADEMIC MEDICAL CENTERS AND TEACHING HOSPITALS**

### **I. INTRODUCTION**

§ 8A:1 Introduction

### **II. THE BAYH-DOLE ACT**

§ 8A:2 Overview

§ 8A:3 Obligations of the AMC Contractor

§ 8A:4 March-In Rights

### **III. TAX-EXEMPT ORGANIZATION ISSUES**

§ 8A:5 Tax-Exempt Organization Issues

§ 8A:6 Tax-Exempt Purpose

§ 8A:7 Private Benefit and Private Inurement

§ 8A:8 Unrelated Business Taxable Income and Private Business Use

### **IV. CONFLICT OF INTEREST**

§ 8A:9 Conflict of Interest

§ 8A:10 Individual Conflicts of Interest

§ 8A:11 Institutional Conflicts

## **CHAPTER 9. TAX-EXEMPT ORGANIZATIONS**

### **I. INTRODUCTION**

§ 9:1 Introduction

### **II. TAX-EXEMPT STATUS**

§ 9:2 Tax-Exempt Status

## TABLE OF CONTENTS

§ 9:3 Defining Financial Assistance and Bad Debt

§ 9:4 Substantial Non-exempt Activities

§ 9:5 Periodic Review of Activities; Oversight

### **III. LOBBYING AND POLITICAL ACTIVITIES**

§ 9:6 Lobbying Activities in General

§ 9:7 Self-Defense Lobbying

§ 9:8 Political Campaign Intervention

§ 9:9 Activities of Non-501(c)(3) Organizations

### **IV. DISCLOSURE OF UNCERTAIN TAX POSITIONS**

§ 9:10 Disclosure of Uncertain Tax Positions

### **V. ADDITIONAL REQUIREMENTS FOR TAX-EXEMPT HOSPITALS UNDER THE AFFORDABLE CARE ACT (ACA)**

§ 9:11 Tax-Exempt Hospitals Under the Affordable Care Act (ACA)

§ 9:12 Section 501(r) Requirements

§ 9:13 Definition of “Hospital Facility” and “Hospital Organization”

§ 9:14 Operation of Hospital Facilities Through Management Contracts, LLCs, and Other Joint Ventures

§ 9:15 Financial Assistance Requirements

§ 9:16 CHNA Requirements

### **VI. EXCESS BENEFIT TRANSACTIONS**

§ 9:17 Excess Benefit Transactions

§ 9:18 Initial Contracts Exception

§ 9:19 Rebuttable Presumption Procedure

§ 9:20 Declaratory Judgment Actions

§ 9:21 Reliance on Professional Advice

§ 9:22 Effective Correction and Preserving Exemption

### **VII. COMPENSATION IN AN EXEMPT ORGANIZATION**

§ 9:23 Incentive Compensation Arrangements

§ 9:24 Excise Tax on Executive Compensation

### **VIII. DEDUCTING COMPENSATION**

§ 9:25 Deducting Compensation

### **IX. PHYSICIAN RECRUITMENT AND RETENTION**

§ 9:26 Physician Recruitment and Retention

**X. MERGERS, ACQUISITIONS AND NONPROFIT CONVERSIONS**

§ 9:27 Mergers, Acquisitions and Nonprofit Conversions

**XI. UNRELATED BUSINESS INCOME (UBI)**

§ 9:28 Unrelated Business Income (UBI)

**XII. JOINT VENTURES**

§ 9:29 Joint Ventures

**XIII. TAX-EXEMPT BONDS**

§ 9:30 Tax-Exempt Bonds

**XIV. EMPLOYMENT TAXES**

§ 9:31 Employment Taxes

**XV. MEDICAL RESIDENT FICA**

§ 9:32 Medical Resident FICA

**XVI. ACCOUNTABLE CARE ORGANIZATIONS (ACOS)**

§ 9:33 Accountable Care Organizations (ACOS)

**XVII. ELECTRONIC MEDICAL RECORDS (EMRS)**

§ 9:34 Electronic Medical Records (EMRS)

§ 9:35 Regional Health Information Exchanges

**XVIII. EFFECT ON TAX-EXEMPT ORGANIZATIONS OF PROVIDING INSURANCE**

§ 9:36 Commercial-Type Insurance

§ 9:37 Liability Insurance

**CHAPTER 9A. GOOD GOVERNANCE FUNDAMENTALS**

§ 9A:1 Introduction

**I. GOVERNANCE PROCESSES**

§ 9A:2 Role of the board

§ 9A:3 Importance of effective board practices

§ 9A:4 Removal of directors

TABLE OF CONTENTS

**II. WEARING TWO HATS—WHEN FIDUCIARY DUTIES AND OTHER INTERESTS COLLIDE**

§ 9A:5 Potential conflict of interest scenarios

**III. FIDUCIARY DUTY CHALLENGES TO HEALTH CARE TRANSACTIONS**

§ 9A:6 Insider compensation

§ 9A:7 Hospital sales and joint ventures

§ 9A:8 Religious hospitals

§ 9A:9 Expanding duties and concerns

§ 9A:10 IRS view of conflicts of interest and good governance

**CHAPTER 10. ENVIRONMENTAL COMPLIANCE IN HEALTH CARE FACILITIES**

**I. INTRODUCTION**

§ 10:1 Environmental risks generally

**II. ENVIRONMENTAL LAWS THAT AFFECT HEALTH CARE FACILITIES**

§ 10:2 Clean Water Act (CWA)

§ 10:3 Resource Conservation and Recovery Act (RCRA)

§ 10:4 Mercury waste

§ 10:5 Clean Air Act (CAA)

§ 10:6 Toxic Substances Control Act (TSCA)

§ 10:7 Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)

§ 10:8 Emergency Planning and Community Right to Know Act (EPCRA)

§ 10:9 EPA's Integrated Data for Enforcement Analysis (IDEA)

**III. COMPLIANCE INCENTIVES**

§ 10:10 Generally

§ 10:11 Environmental audits

§ 10:12 Systematic discovery

§ 10:13 Voluntary discovery

§ 10:14 Prompt disclosure

§ 10:15 Independent discovery and disclosure

§ 10:16 Correction and remediation

§ 10:17 Ineligibility of repeat violations

§ 10:18 Ineligibility of certain types of violations

- § 10:19 Cooperation
- § 10:20 The key to success: Environmental Management Systems (EMS)
- § 10:21 Pollution prevention programs

#### **IV. INSPECTIONS**

- § 10:22 What to expect
- § 10:23 Warrantless inspections
- § 10:24 Search warrant inspections

#### **V. ENVIRONMENTAL ASPECTS OF ACCREDITATION FOR HEALTH CARE ORGANIZATIONS**

- § 10:25 The Joint Commission accreditation and its “Environment of Care” standards

#### **VI. THE SIGNIFICANCE FOR IN-HOUSE COUNSEL, THE GOVERNING BOARD, AND EXECUTIVE LEADERSHIP**

- § 10:26 Significance of compliance

#### **VII. KEY RECOMMENDATIONS**

- § 10:27 Key recommendations

#### **VIII. CONCLUSION**

- § 10:28 Conclusion

Appendix 10-A. Recordkeeping Requirements for many of the Relevant Environmental Regulations Discussed in Chapter 10

## **PART II. PATIENT CARE DELIVERY ISSUES**

### **CHAPTER 11. PATIENTS’ RIGHTS ISSUES**

#### **I. INTRODUCTION**

- § 11:1 The patient/provider relationship
- § 11:2 Creation of the provider-patient relationship
- § 11:3 Requirement that health care facilities and individual providers accept patients
- § 11:4 Emergency treatment
- § 11:5 Non-emergency treatment

## TABLE OF CONTENTS

§ 11:6 Conscience laws

### **II. CONSENT TO MEDICAL TREATMENT**

- § 11:7 Generally
- § 11:8 Requirements for consent form
- § 11:9 Disclosure of special risk factors of providers
- § 11:10 Exceptions to the requirement to obtain consent
- § 11:11 Statutes requiring special circumstances
- § 11:12 Restraint and seclusion
- § 11:13 Constitutional protection
- § 11:14 Incompetent's right to make treatment decisions
- § 11:15 Minors
- § 11:16 Consent for experimentation

### **III. END-OF-LIFE DECISIONMAKING**

- § 11:17 Competent person's right to refuse life-sustaining medical treatment
- § 11:18 Incompetent patients
- § 11:19 Damages for rendering unwanted care
- § 11:20 Advance directives
- § 11:21 Living wills
- § 11:22 Durable powers of attorney for health care
- § 11:23 Do-not-resuscitate protocols
- § 11:24 Medical futility
- § 11:25 Physician-assisted death

### **IV. DISCLOSURE AND PROTECTION OF PATIENT MEDICAL INFORMATION**

- § 11:26 Patient confidentiality
- § 11:27 Mandatory disclosure
- § 11:28 Judicial disclosure
- § 11:29 Mandatory reporting of medical conditions and duty to warn
- § 11:30 HIPAA privacy rules
- § 11:31 Administrative requirements and training
- § 11:32 Use and disclosure of protected health information
- § 11:33 Patient rights under HIPAA
- § 11:34 Notice of privacy practices
- § 11:35 Breach notification
- § 11:36 Business associate agreements and policies
- § 11:37 Sanctions and enforcement

### **V. CONCLUSION**

- § 11:38 In general

## **CHAPTER 11A. INDIVIDUAL RIGHTS**

- § 11A:1 Introduction
- § 11A:2 The Patient Self Determination Act
- § 11A:3 Advance directives
- § 11A:4 Capacity
- § 11A:5 Consent
- § 11A:6 The informed consent requirement
- § 11A:7 Exceptions to the informed consent requirement
- § 11A:8 Decision making for patients who lack capacity
- § 11A:9 Unrepresented patients
- § 11A:10 Minors
- § 11A:11 End-of-life issues
- § 11A:12 End-of-life care
- § 11A:13 Aid in dying
- § 11A:14 Conscience conflicts and staff's right to refuse to provide care
- § 11A:15 Involuntary and voluntary psychiatric holds and treatment
- § 11A:16 Confidentiality
- § 11A:17 Evolving legal rights: The right to treatment
- § 11A:18 Patient status and specific legal issues
- § 11A:19 Forensic (Criminal) patients
- § 11A:20 Minors
- § 11A:21 Risk avoidance and mitigation in psychiatric care

## **CHAPTER 11B. IMMIGRANT HEALTH CARE**

- § 11B:1 Introduction: what is a public charge?
- § 11B:2 Department of state: foreign affairs manual
- § 11B:3 Department of homeland security: public charge
- § 11B:4 Definition of a public charge
- § 11B:5 Definition of public benefit
- § 11B:6 Totality of circumstances test
- § 11B:7 Prioritization of immigrants with wealth
- § 11B:8 Department of justice: deportability
- § 11B:9 Department of housing and urban development: eligibility

## **CHAPTER 12. ADVANCING INCLUSIVITY AND EQUITY IN ACCOUNTABLE CARE ORGANIZATIONS INITIATIVES**

- § 12:1 Introduction

### **I. CMS EFFORTS TO ADVANCE INCLUSIVITY AND EQUITY IN ACO INITIATIVES**

- § 12:2 Medicare Shared Savings Program

## TABLE OF CONTENTS

- § 12:3 Recent efforts to advance inclusivity and equity
- § 12:4 Center for Medicare and Medicaid Innovation
- § 12:5 CMMI's ACO models
- § 12:6 CMMI's new commitment to equity
- § 12:7 ACO REACH Model
- § 12:8 Vermont All-Payer ACO Model
- § 12:9 The Vermont all payer ACO model
- § 12:10 Green Mountain Care Board's strong regulatory oversight
- § 12:11 OneCare Vermont Accountable Care Organization, LLC

## II. COMMON LEGAL ISSUES AND PRACTICE TIPS

- § 12:12 Governance
- § 12:13 Networks and financial arrangements—Forming a Provider Network
- § 12:14 Patient engagement incentives
- § 12:15 Enhanced benefits
- § 12:16 Data sharing and performance measurement
- § 12:17 Quality measurement
- § 12:18 Beneficiary protections
- § 12:19 State law considerations

## CHAPTER 13. DISPUTE RESOLUTION

- § 13:1 Introduction
- § 13:2 Arbitration
- § 13:3 Potential advantages
- § 13:4 Realizing time and cost savings
- § 13:5 Getting cases into arbitration
- § 13:6 Employment and consumer disputes
- § 13:7 Agreements with employees
- § 13:8 Agreements with consumers
- § 13:9 Nursing home statutes and regulations
- § 13:10 Limitations on consumer choice
- § 13:11 Authority to agree to arbitration
- § 13:12 Rules of procedure
- § 13:13 Arbitration: summary
- § 13:14 Mediation
- § 13:15 Advantages for health law cases
- § 13:16 Mediating effectively
- § 13:17 Agreeing to mediate
- § 13:18 Selecting a mediator
- § 13:19 Preparing for mediation
- § 13:20 Combining mediation and arbitration
- § 13:21 Mediation: summary
- § 13:22 Conflict management

§ 13:23 Conclusion

## **CHAPTER 14. EMTALA COMPLIANCE**

### **I. INTRODUCTION**

§ 14:1 Generally

### **II. OVERVIEW**

#### **A. OVERVIEW OF EMTALA'S PRINCIPAL STATUTORY REQUIREMENTS AND REGULATIONS**

- § 14:2 Statutory purpose
- § 14:3 Medical screening examination
- § 14:4 Compliance pointers for medical screening examinations
- § 14:5 Stabilization
- § 14:6 Compliance pointers for stabilization
- § 14:7 Appropriate transfer
- § 14:8 Compliance pointers for transfers

### **III. ADDITIONAL STATUTORY REQUIREMENTS**

- § 14:9 Duty to accept transfers (reverse-dumping)
- § 14:10 Compliance pointers for reverse dumping requirements
- § 14:11 Central log
- § 14:12 Compliance pointers for ED log requirements
- § 14:13 Signs
- § 14:14 Compliance pointers for signage requirements
- § 14:15 On-call list
- § 14:16 Compliance pointers for physicians' on-call obligations
- § 14:17 Whistleblower protection

### **IV. SPECIAL ADVISORY BULLETIN**

§ 14:18 OIG special advisory bulletin

### **V. ADDITIONAL COMPLIANCE CONSIDERATIONS**

- § 14:19 Dedicated emergency department and hospital property
- § 14:20 Urgent care centers
- § 14:21 Ground and air ambulances
- § 14:22 Off-campus sites
- § 14:23 Application to inpatients

TABLE OF CONTENTS

- § 14:24 Nonemergency services
- § 14:25 EMTALA obligations during disasters
- § 14:26 Working with law enforcement
- § 14:27 Compliance pointers for working with law enforcement

**VI. SUBSTANCE USE DISORDER AND PSYCHIATRIC PATIENTS**

- § 14:28 Medication seeking patients
- § 14:29 Signage
- § 14:30 Communicating about treatment

**VII. ENFORCEMENT, PENALTIES, AND REPORTING UNDER EMTALA**

- § 14:31 Generally
- § 14:32 Reporting
- § 14:33 Compliance pointers for reporting requirements

**VIII. COMPLIANCE, EDUCATION, AND TRAINING**

- § 14:34 Education and training
- § 14:35 EMTALA audits
- § 14:36 The baseline EMTALA audit
- § 14:37 Ongoing or periodic audits
- § 14:38 Audits of EMTALA complaints
- § 14:39 Suggested EMTALA documents
- § 14:40 Conclusion

**CHAPTER 15. BIOETHICS**

**I. INTRODUCTION**

- § 15:1 Bioethics generally

**II. HUMAN REPRODUCTION**

- § 15:2 Abortion—*Roe v. Wade*
- § 15:3 Post-*Roe v. Wade* developments
- § 15:4 The transformation of *Roe*
- § 15:5 Medical and emergency abortion
- § 15:6 Access to abortion facilities
- § 15:7 Informed-consent laws redux
- § 15:8 Access to contraceptives
- § 15:9 Commercial surrogacy
- § 15:10 Prohibition and regulation
- § 15:11 Custody disputes

**III. ORGAN TRANSPLANTATION**

- § 15:12 Strategies to increase the supply of organs
- § 15:13 Allocation policies
- § 15:14 The new genetics
- § 15:15 Confidentiality
- § 15:16 Nondiscrimination
- § 15:17 Insurance
- § 15:18 Employment
- § 15:19 Genetic engineering
- § 15:20 Embryonic and fetal-cell research
- § 15:21 Cloning
- § 15:22 Conclusion

**CHAPTER 15A. REPRODUCTIVE HEALTH LAW****I. INTRODUCTION**

- § 15A:1 Abortion
- § 15A:2 Abortion and *Roe v. Wade*
- § 15A:3 Post-*Roe v. Wade* developments
- § 15A:4 The transformation of *Roe v. Wade*
- § 15A:5 The end of *Roe v. Wade* and *Casey*
- § 15A:6 Abortion law after *Dobbs*
- § 15A:7 Medical abortion and emergency contraception
- § 15A:8 Access to abortion facilities
- § 15A:9 Informed-consent laws redux
- § 15A:10 Access to contraceptives
- § 15A:11 Reproductive health care privacy

**II. COMMERCIAL SURROGACY**

- § 15A:12 Public policy history of surrogacy
- § 15A:13 Prohibition and regulation of commercial surrogacy
- § 15A:14 Custody disputes

**CHAPTER 16. DRUGS, DEVICES, AND LIFE SCIENCES ENTITIES**

- § 16:1 Introduction
- § 16:2 FDA standards—Promotional activities
- § 16:3 Off-label promotion
- § 16:4 Superiority claims
- § 16:5 Direct-to-consumer advertising
- § 16:6 Pre-approval promotion
- § 16:7 Payor/formulary committee communications
- § 16:8 Safety reporting

## TABLE OF CONTENTS

- § 16:9 The Prescription Drug Marketing Act
- § 16:10 Relationships with health care professionals and customers
- § 16:11 Anti-kickback exceptions and safe harbor regulations
- § 16:12 Discount safe harbor
- § 16:13 Personal services and management contracts, and space and equipment rental
- § 16:14 Warranty safe harbor
- § 16:15 Industry Codes of Ethics
- § 16:16 OIG guidance
- § 16:17 Manufacturer reimbursement support programs and patient assistance programs
- § 16:18 Cost-sharing subsidies
- § 16:19 Part D beneficiaries
- § 16:20 Joint ventures; physician-owned distributors
- § 16:21 Sunshine Reporting: Physician Payment Sunshine Act and state law reporting
- § 16:22 State laws limiting manufacturer relationships with health care professionals
- § 16:23 Pricing and contracting compliance
- § 16:24 List pricing scrutiny
- § 16:25 *In re Pharmaceutical Industry Average Wholesale Price Litigation*
- § 16:26 Recent list price challenges
- § 16:27 Legislative scrutiny
- § 16:28 Indirect challenges
- § 16:29 Government pricing programs—Medicaid rebate program
- § 16:30 Public Health Service 340B Program
- § 16:31 Veterans Health Care Act
- § 16:32 Medicare Part B average sales price
- § 16:33 Medicare Part D coverage gap discounts
- § 16:34 Contracting and discounts
- § 16:35 Erosion of the anti-kickback discount safe harbor
- § 16:36 Exclusive formulary contracting
- § 16:37 Middleman contracting
- § 16:38 Miscellaneous compliance issues for manufacturers—Relationships with distributors and wholesalers
- § 16:39 Data privacy and security
- § 16:40 Foreign Corrupt Practices Act

## **CHAPTER 17. BEHAVIORAL HEALTH LAW**

- § 17:1 Introduction
- § 17:2 Mental disorders
- § 17:3 Substance use disorders
- § 17:4 Licensure and provision of treatment
- § 17:5 Practice under state licensure laws

§ 17:6	Scope of coverage
§ 17:7	Exemptions
§ 17:8	Treatment levels
§ 17:9	Privacy, security, and confidentiality
§ 17:10	HIPAA
§ 17:11	42 C.F.R. Part 2
§ 17:12	Program
§ 17:13	Patient information
§ 17:14	Notice
§ 17:15	Consent
§ 17:16	Exceptions to the consent requirement
§ 17:17	Revised Rule of 2017
§ 17:18	Final Rule of 2018
§ 17:19	State mental health laws
§ 17:20	Reimbursement and managed care
§ 17:21	Medicaid
§ 17:22	Certification
§ 17:23	Fraud and abuse
§ 17:24	IMD exclusion
§ 17:25	Medicaid managed care
§ 17:26	Medicare
§ 17:27	Private insurance
§ 17:28	Grant funding
§ 17:29	Mental Health Parity and Addiction Equity Act
§ 17:30	Conclusion

# Table of Contents

## **PART III. PAYMENT ISSUES**

### **CHAPTER 18. FUNDAMENTALS OF COMMERCIAL HEALTH INSURANCE\***

#### **I. INTRODUCTION**

§ 18:1 Scope of “Commercial Health Insurance”

#### **II. KEY INSURANCE CONCEPTS**

- § 18:2 Definition of “Insurance”
- § 18:3 Definition of “Health Insurance”
- § 18:4 Risk pools
- § 18:5 Adverse selection
- § 18:6 Death spirals
- § 18:7 Risk Management strategies
- § 18:8 Insurance premium rates
- § 18:9 Health care provider payments
- § 18:10 Administrative costs
- § 18:11 Group and non-group markets
- § 18:12 Health insurance exchange markets
- § 18:13 Fully insured and self-insured coverage

#### **III. U.S. COMMERCIAL HEALTH INSURANCE MARKET**

- § 18:14 Major regulators of commercial health insurance
- § 18:15 Health insurers, benefit managers, and other vendors

#### **IV. REGULATION OF COMMERCIAL HEALTH INSURANCE INDUSTRY AND MARKETS**

- § 18:16 Federal and State Jurisdiction
- § 18:17 Relationship of federal and state insurance laws
- § 18:18 McCarran-Ferguson Act
- § 18:19 The Employee Retirement Income Security Act of  
1974
- § 18:20 Other federal statutes related to insurance
- § 18:21 Federal laws regulating commercial health insurance
- § 18:22 State laws regulating commercial health insurance

- § 18:23 Licensure
- § 18:24 Solvency; risk-based capital
- § 18:25 Forms and rate filings
- § 18:26 Annual and other filing requirements
- § 18:27 Market conduct; financial examination; corrective action
- § 18:28 Sales; mergers; asset purchases; wind-downs
- § 18:29 Conservation, rehabilitation, and liquidation
- § 18:30 Consumer protections: Access, costs, and coverage

## **V. CONCLUSION**

- § 18:31 Complex Regulatory Framework
- § 18:32 Table 1. Private Health Insurance Market Reforms under the Patient Protection and Affordable Care Act (ACA)

# **CHAPTER 19. STATE AND FEDERAL REGULATION OF PRIVATE HEALTHCARE PLANS**

## **I. THE BASIS OF REGULATION**

- § 19:1 The state regulation of the business of insurance
- § 19:2 McCarran-Ferguson Act
- § 19:3 State case law
- § 19:4 “Business of Insurance” according to SCOTUS
- § 19:5 Federal regulation and the pre-emption of state laws
- § 19:6 ERISA preemption provision
- § 19:7 ERISA preemption case law and analytical framework
- § 19:8 Travelers Insurance Co.
- § 19:9 Metropolitan Life Insurance Co.
- § 19:10 Unum Life Insurance Co.
- § 19:11 Kentucky Association of Health Plans, Inc.
- § 19:12 “Saving Clause” and “Deemer” clause analysis
- § 19:13 State laws affecting Health Maintenance Organization (HMO) operations
- § 19:14 Rush Prudential HMO, Inc.
- § 19:15 Pegram v. Herdrich
- § 19:16 “Any Willing Provider” Laws

## **II. STATE REGULATION OF PRIVATE HEALTHCARE PLANS**

- § 19:17 Indemnity insurers
- § 19:18 Preferred provider organizations

## TABLE OF CONTENTS

- § 19:19 Health Maintenance Organizations
- § 19:20 —Distinctions between HMOs and indemnity plans
- § 19:21 —Monitoring participating provider performance
- § 19:22 —Staff model
- § 19:23 —Group model
- § 19:24 —Network model
- § 19:25 —IPA model
- § 19:26 —Direct Contract model
- § 19:27 —Risk-sharing arrangements
- § 19:28 —Withhold arrangements
- § 19:29 —Bonus arrangements
- § 19:30 —Capitation arrangements
- § 19:31 —Percent-of-premium arrangements
- § 19:32 —Pool/Fund arrangements
- § 19:33 —Scope of state regulation
- § 19:34 —Typical areas of regulation
- § 19:35 Point-of-Service programs
- § 19:36 Third-Party Administrators (TPA)
- § 19:37 Provider-Sponsored Networks (PSN)
- § 19:38 Blue Cross and Blue Shield (BC/BS) Plans

## **III. THE FEDERAL REGULATION OF PRIVATE HEALTHCARE PLANS**

- § 19:39 Background
- § 19:40 ERISA—COBRA
- § 19:41 —Mental Health Parity Act
- § 19:42 —HIPAA’s pre-existing condition rule
- § 19:43 —HIPAA’s privacy rules
- § 19:44 —Qualified medical child support orders
- § 19:45 —Coverage for adopted children
- § 19:46 —Coverage for pediatric vaccines
- § 19:47 —Maternity protection
- § 19:48 —Minimum cancer treatment
- § 19:49 The Patient Protection and Affordable Care Act
- § 19:50 No lifetime or annual coverage limits
- § 19:51 Prohibition on rescission
- § 19:52 The appeals process
- § 19:53 Coverage of preventative health services
- § 19:54 Extension of dependent coverage
- § 19:55 Standardization of coverage documents
- § 19:56 Information regarding transparency
- § 19:57 Prohibition of discrimination in favor of highly compensated individuals
- § 19:58 Reporting; quality of care
- § 19:59 Essential benefits coverage
- § 19:60 Prohibition on excessive waiting period

- § 19:61 Prohibition of pre-existing condition based on health status
- § 19:62 Prohibition of discrimination against individual participants and beneficiaries based on health status
- § 19:63 Tax credit for small business
- § 19:64 Automatic enrollment for employees of large employers
- § 19:65 Employer requirement to inform employees of coverage options
- § 19:66 Shared responsibility
- § 19:67 Reporting employer health insurance coverage
- § 19:68 Cafeteria plan changes
- § 19:69 Conclusion

## **CHAPTER 19A. OVERPAYMENT RECOVERIES BY HEALTH INSURERS**

### **I. INTRODUCTION**

- § 19A:1 Generally

### **II. PRACTICAL AND REGULATORY FRAMEWORK**

- § 19A:2 Generally

### **III. BEST PRACTICES FOR HEALTH PLANS AND PROVIDERS**

- § 19A:3 Legal theories
- § 19A:4 Basis for recovery
- § 19A:5 Health plan best practices
- § 19A:6 Provider best practices
- § 19A:7 Is there a proper basis for recovery—Determining the merits
- § 19A:8 Determining the scope of the recovery
- § 19A:9 Sampling methodology

### **IV. CONCLUSION**

- § 19A:10 Generally

## **CHAPTER 19B. FULL DISCLOSURE: HOSPITAL PRICE TRANSPARENCY AND SURPRISE BILLING**

- § 19B:1 Introduction

### **I. HOSPITAL PRICE TRANSPARENCY RULE**

- § 19B:2 Legislative overview of the hospital price transparency rule

## TABLE OF CONTENTS

- § 19B:3 Regulatory history
- § 19B:4 Key components
- § 19B:5 American hospital association litigation

## **II. NO SURPRISES ACT**

- § 19B:6 Legislative overview of the No Surprise Act
- § 19B:7 Good faith estimates for uninsured and self-pay patients
- § 19B:8 Patient consent for out-of-network billing
- § 19B:9 Independent dispute resolution of health plan out-of-network reimbursement

## **CHAPTER 20. OVERVIEW OF MEDICARE**

### **I. INTRODUCTION**

- § 20:1 Introduction
- § 20:2 Program structure
- § 20:3 Basic eligibility
- § 20:4 Buying Medicare coverage
- § 20:5 State payment of premiums and cost sharing

### **II. GOVERNMENT AGENCIES THAT ADMINISTER MEDICARE**

- § 20:6 Government agencies that administer Medicare
- § 20:7 Centers for Medicare & Medicaid Services (CMS)
- § 20:8 HHS Office of Inspector General (OIG)
- § 20:9 Social Security Administration
- § 20:10 Departmental Appeals Board

### **III. MEDICARE CONTRACTORS**

- § 20:11 Medicare contractors
- § 20:12 Claims processing contractors
- § 20:13 Medicare Integrity Program
- § 20:14 Qualified Independent Contractors
- § 20:15 Quality improvement organizations (QIOs)
- § 20:16 Recovery Audit Contractors
- § 20:17 State agencies
- § 20:18 ESRD network organizations

### **IV. LITIGATION AGAINST MEDICARE CONTRACTORS AND DEFENSES**

- § 20:19 Overview
- § 20:20 Non-FCA cases
- § 20:21 FCA cases

## **V. ADVISORY COMMITTEES**

- § 20:22 MedPAC
- § 20:23 Independent Payment Advisory Board
- § 20:24 Carrier advisory committees

## **VI. ADMINISTRATIVE PROCESS**

- § 20:25 Issuance of regulations
- § 20:26 Manuals and other administrative issuances
- § 20:27 Effective date of policy changes

## **VII. TERMINOLOGY**

- § 20:28 Providers and suppliers
- § 20:29 Coverage, payment, and reimbursement
- § 20:30 Cost sharing, coinsurance, copayments, deductible, and balance billing
- § 20:31 Prospective payment system
- § 20:32 Claim and bill
- § 20:33 Cost reporting period

# **CHAPTER 21. MEDICARE PROSPECTIVE PAYMENT SYSTEM FOR INPATIENT OPERATING COSTS**

## **I. INTRODUCTION**

- § 21:1 Introduction to prospective payment system

## **II. DRGS AND MS-DRGS**

- § 21:2 Generally
- § 21:3 DRG/MS-DRG classification and weighting—History and background
- § 21:4 MS-DRG assignment
- § 21:5 Recalibration

## **III. STANDARDIZED AMOUNTS**

- § 21:6 Generally
- § 21:7 Initial calculation of the standardized amounts
- § 21:8 Updating the standardized amounts
- § 21:9 Payment adjustments for quality initiatives and the Medicare Promoting Interoperability Program
- § 21:10 Rebasing and restandardizing

## **IV. PPS TRANSITION PERIOD**

- § 21:11 Phase-in

## TABLE OF CONTENTS

- § 21:12 Determination of hospital-specific rate
- § 21:13 Finality of hospital-specific rate
- § 21:14 Changed circumstances following the base year
- § 21:15 New hospitals
- § 21:16 Regional floors

## **V. WAGE INDEX**

- § 21:17 Generally
- § 21:18 Impact
- § 21:19 “Geographic area”
- § 21:20 Wage data
- § 21:21 Occupational mix
- § 21:22 Corrections to wage data
- § 21:23 Revisions to the hospital wage index

## **VI. OUTLIER PAYMENTS**

- § 21:24 Generally
- § 21:25 The outlier pool
- § 21:26 Outlier thresholds and marginal costs
- § 21:27 Phasing out day outliers

## **VII. INDIRECT MEDICAL EDUCATION**

- § 21:28 Generally
- § 21:29 Counting interns and residents and beds
- § 21:30 Computing the IME payment amount

## **VIII. SPECIAL RURAL HOSPITALS**

- § 21:31 Generally
- § 21:32 Sole community hospitals—Criteria for classification
- § 21:33 —SCH payment
- § 21:34 Referral centers
- § 21:35 Small Medicare-dependent hospitals
- § 21:36 Critical access hospitals

## **IX. DISPROPORTIONATE SHARE**

- § 21:37 Generally
- § 21:38 DSH criteria
- § 21:39 DSH payment adjustment
- § 21:40 Days included in the DPP
- § 21:41 Uncompensated Care Pool Payment

## **X. GEOGRAPHIC RECLASSIFICATION**

- § 21:42 Generally

- § 21:43 CMS discretion
- § 21:44 “Lugar counties”
- § 21:45 The Medicare Geographic Classification Review Board
- § 21:46 Geographic criteria for MGCRB reclassification
- § 21:47 Economic criteria for MGCRB wage index reclassifications
- § 21:48 Standardized amount reclassification
- § 21:49 Group reclassification applications
- § 21:50 Application withdrawals and terminations
- § 21:51 Section 508 wage index reclassification
- § 21:52 Wage index adjustment based on commuting patterns
- § 21:53 Goldsmith modification reclassifications

## **XI. PUERTO RICO**

- § 21:54 Generally

## **CHAPTER 22. MEDICARE PROSPECTIVE PAYMENT SYSTEM FOR INPATIENT HOSPITAL CAPITAL COSTS**

### **I. LEGISLATIVE BACKGROUND**

- § 22:1 Overview

### **II. SCOPE OF REGULATIONS**

- § 22:2 Generally

### **III. PAYMENT METHODOLOGIES**

- § 22:3 Overview

### **IV. SIGNIFICANCE OF “REASONABLE COST” PRINCIPLES**

- § 22:4 Generally

### **V. IDENTIFICATION OF OLD CAPITAL COSTS**

- § 22:5 Generally

### **VI. ASSETS IN OPERATION BY DECEMBER 31, 1990**

- § 22:6 Overview
- § 22:7 Depreciation
- § 22:8 Capital-related interest expense

TABLE OF CONTENTS

- § 22:9 Leases and rentals
- § 22:10 Other capital-related costs
- § 22:11 Related party capital costs
- § 22:12 Expansion of patient care usage of asset
- § 22:13 Change of ownership

**VII. OBLIGATED CAPITAL**

- § 22:14 Generally
- § 22:15 Obligation
- § 22:16 Date of operation
- § 22:17 Intermediary notification
- § 22:18 Limitations as to amount
- § 22:19 Possibility of inconsistent characterizations

**VIII. SPECIAL EXCEPTION CATEGORY OF OLD CAPITAL**

- § 22:20 Generally

**IX. PAYMENT UNDER THE FEDERAL RATE AND THE HOSPITAL-SPECIFIC RATE**

- § 22:21 Generally

**X. REDETERMINATION OF HOSPITAL-SPECIFIC RATE**

- § 22:22 Overview
- § 22:23 Prerequisite for redetermination
- § 22:24 Increases in old capital costs
- § 22:25 Years subject to a redetermination request
- § 22:26 Process for requesting a redetermination
- § 22:27 Special redetermination process for fiscal year 1994

**XI. EXCEPTION PAYMENTS**

- § 22:28 Generally
- § 22:29 Standard exception
- § 22:30 Extraordinary circumstances exception
- § 22:31 Special exception for major construction undertaken and completed during transition period

**XII. NEW HOSPITALS**

- § 22:32 Summary

## **CHAPTER 23. GRADUATE MEDICAL EDUCATION REIMBURSEMENT**

### **I. MEDICARE PAYMENTS ASSOCIATED WITH MEDICAL RESIDENTS**

- § 23:1 Legislative history
- § 23:2 Limiting interpretations
- § 23:3 Changes under the Affordable Care Act (ACA)

### **II. CURRENT GME RULES**

- § 23:4 What are DGME and IME payments?
- § 23:5 Calculation of DGME payments
- § 23:6 IME payments
- § 23:7 Resident counts
- § 23:8 Initial residency period
- § 23:9 Resident FTE limits—“Historic” or “1996” caps
- § 23:10 Medicare GME affiliation agreements
- § 23:11 Resident FTE limits—Rolling averages
- § 23:12 Redistribution of unused resident slots
- § 23:13 Redistribution of slots from closed hospitals
- § 23:14 New programs
- § 23:15 Hospital residents training in off-site/non-provider locations
- § 23:16 Research, didactic, and other leave time
- § 23:17 DGME and IME payments associated with medicare managed care enrollees

### **III. LITIGATION AND COMPLIANCE ISSUES**

- § 23:18 Research time
- § 23:19 Non-provider training (Pre-ACA)
- § 23:20 New programs
- § 23:21 Revisiting prior CAP/PRA determinations—Reopening predicate facts
- § 23:22 Part B reasonable cost reimbursement for fellows

## **CHAPTER 24. FUNDAMENTALS OF MEDICARE PARTS A AND B**

### **I. INTRODUCTION**

- § 24:1 Generally

### **II. KEY TERMS**

- § 24:2 Generally

TABLE OF CONTENTS

**III. MEDICARE’S FOUR PARTS**

§ 24:3 Generally

**IV. ELIGIBILITY FOR MEDICARE BENEFITS**

§ 24:4 Part A

§ 24:5 Part B

**V. COVERAGE**

§ 24:6 Part A coverage

§ 24:7 Hospital services (inpatient)

§ 24:8 Inpatient admissions, observation services and the  
“Two Midnight Rule”

§ 24:9 Extended care services in a Skilled Nursing Facility  
 (“SNF”)

§ 24:10 Home health care services

§ 24:11 Hospice services

§ 24:12 Coverage determinations

§ 24:13 Part B coverage

§ 24:14 Non-physician practitioner services

§ 24:15 Services furnished by specific types of facilities

§ 24:16 Drugs and biologicals

§ 24:17 Home health services

§ 24:18 DMEPOS

§ 24:19 Other Part B covered services

**VI. CERTIFICATION AND ENROLLMENT**

§ 24:20 How does a provider participate in the medicare  
 program?

**VII. PAYMENT**

§ 24:21 Payment under Part A

§ 24:22 Calculating the hospital’s IPPS payment

§ 24:23 Rural-area hospitals

§ 24:24 Specialty hospitals

§ 24:25 Graduate medical education

§ 24:26 SNF PPS

§ 24:27 Home health agencies PPS

§ 24:28 Hospice prospective payment

§ 24:29 Payment under Part B

§ 24:30 Hospital outpatient services

§ 24:31 Physician services

§ 24:32 Clinical laboratory services

§ 24:33 Ambulatory surgery centers

§ 24:34 Part B drugs and biologicals

- § 24:35 DMEPOS
- § 24:36 How medicare payments are made
- § 24:37 Claim submission and payment
- § 24:38 Claim appeals
- § 24:39 Importance of conditions of participation and conditions for coverage

## **VIII. MEDICARE'S IMPACT ON HEALTH CARE TRANSACTIONS**

- § 24:40 Generally
- § 24:41 Change of ownership
- § 24:42 Change of information
- § 24:43 Keeping medicare updated regarding provider changes

## **IX. ASSISTING PROVIDERS WITH MEDICARE QUESTIONS**

- § 24:44 Generally
- § 24:45 MACs
- § 24:46 CMS regional offices

Appendix 24A. Acronyms

# **CHAPTER 25. PAYMENT OF PHYSICIAN SERVICES**

## **I. INTRODUCTION**

- § 25:1 Introduction

## **II. OVERVIEW OF PAYMENT SYSTEMS**

- § 25:2 Overview of payment systems
- § 25:3 Health insurance companies
- § 25:4 Health maintenance organizations
- § 25:5 Managed care plans
- § 25:6 Worker's compensation
- § 25:7 Government health insurance programs
- § 25:8 Medicare—Parts A and B
- § 25:9 Medicare Part C—Medicare Advantage Plans
- § 25:10 Medicare Part D
- § 25:11 Medicaid

## **III. PAYMENT FOR HEALTH SERVICES**

- § 25:12 Overview of payment systems
- § 25:13 Fee-for-service

## TABLE OF CONTENTS

§ 25:14	Discounted fee-for-service
§ 25:15	Capitation payments
§ 25:16	Pay-for-performance and ratings-based payment
§ 25:17	—What they are
§ 25:18	—What they measure
§ 25:19	—What they pay
§ 25:20	—Evaluating likely compensation and success
§ 25:21	Medicare Part B payments
§ 25:22	Enrollment of physician in Medicare
§ 25:23	Accepting assignment under Medicare
§ 25:24	Reimbursement of Medicare claims
§ 25:25	—Resource based relative value units
§ 25:26	—Geographic practice cost indices
§ 25:27	—Pricing localities for Medicare Part B
§ 25:28	—National Conversion Factor
§ 25:29	Coding for Medicare Part B services
§ 25:30	Documentation of services
§ 25:31	Claims—Evaluation and management documentation
§ 25:32	Clean claims under Medicare
§ 25:33	Billing for auxiliary personnel under Medicare
§ 25:34	Billing for ancillary services under Medicare
§ 25:35	Medicare as a secondary payer
§ 25:36	The Physician Quality Reporting Initiative/System
§ 25:37	Meaningful use adjustments

## **IV. NEW PAYMENT MODELS UNDER THE ACA**

§ 25:38	New payment models under the ACA
§ 25:39	National Pilot Program on Payment Bundling
§ 25:40	Medicare Shared Savings Program
§ 25:41	Value based modifier under the Physician Fee Schedule
§ 25:42	Center for Medicare and Medicaid Innovation

## **V. PROMPT PAYMENT LAWS AND REIMBURSEMENT**

§ 25:43	Overview of prompt payment laws
§ 25:44	Problems that arise for reimbursement under prompt payment laws
§ 25:45	Avoiding prompt payment disputes

## **VI. RECOVERY OF OVERPAYMENTS**

§ 25:46	Overview of overpayments
§ 25:47	Internal practice protocols
§ 25:48	Overpayments from Medicare
§ 25:49	Suspension of payments

§ 25:50 Recovery Audit Contractors

## **VII. PART B DETERMINATIONS AND APPEALS**

§ 25:51 Part B determinations and appeals

## **VIII. CONCLUSION**

§ 25:52 Conclusion

# **CHAPTER 26. FUNDAMENTALS OF MEDICARE PARTS C AND D**

## **I. INTRODUCTION AND LEGISLATIVE HISTORY**

§ 26:1 Generally

## **II. MEDICARE ADVANTAGE**

§ 26:2 Overview of medicare advantage program

§ 26:3 MA plan options

§ 26:4 Bidding and payments for medicare advantage organizations

§ 26:5 Medicare advantage supplemental benefits

§ 26:6 Eligibility for and enrollment into medicare advantage

§ 26:7 Medicare advantage provider networks

## **III. MEDICARE PRESCRIPTION DRUG BENEFIT (PART D)**

§ 26:8 Overview of the Part D program

§ 26:9 Bidding and payments for Part D sponsors

§ 26:10 Part D benefits

§ 26:11 Part D Eligibility and Enrollment

## **IV. MEDICARE ADVANTAGE AND PART D OPERATIONAL TOPICS**

§ 26:12 Compliance Programs

§ 26:13 Appeals, grievances, and inquiries

§ 26:14 Star ratings

§ 26:15 Marketing and other beneficiary communications

# **CHAPTER 26A. 340B PROGRAM ISSUES**

## **I. INTRODUCTION**

§ 26A:1 Overview of the 340B program

§ 26A:2 Purpose and intent of the program

## TABLE OF CONTENTS

- § 26A:3 Operation of the 340B program
- § 26A:4 Wholesalers and the prime vendor
- § 26A:5 Sources of law and guidance

## **II. 340B PROGRAM ELIGIBILITY BASICS**

- § 26A:6 Program eligibility overview
- § 26A:7 Types of covered entities

## **III. SPECIFIC ELIGIBILITY CRITERIA**

- § 26A:8 Categories of eligible providers
- § 26A:9 Hospitals
- § 26A:10 Organizational status
- § 26A:11 Prohibition against group purchasing
- § 26A:12 Grantees and FQHC look-Alikes

## **IV. PROGRAM PARTICIPATION FOR COVERED ENTITIES**

- § 26A:13 Registration

## **V. KEY COVERED ENTITY REQUIREMENTS**

- § 26A:14 Overview
- § 26A:15 Diversion
- § 26A:16 Duplicate discounts
- § 26A:17 State medicaid reimbursement policies
- § 26A:18 Medicaid managed care policies
- § 26A:19 Prohibition on group purchasing
- § 26A:20 Orphan drugs
- § 26A:21 Inventory management

## **VI. ADDITIONAL REQUIREMENTS FOR COVERED ENTITIES**

- § 26A:22 OPA database entries
- § 26A:23 Auditable records
- § 26A:24 Annual recertification

## **VII. MANUFACTURER REQUIREMENTS**

- § 26A:25 Discounted drug prices for covered entities
- § 26A:26 Protections for covered entities against overcharging

## **VIII. CONTRACT PHARMACIES**

- § 26A:27 Contract pharmacy guidelines
- § 26A:28 Manufacturer opposition to contract pharmacy distribution

## **IX. 340B PROGRAM AUDITS**

- § 26A:29 HRSA and manufacturer audit authority
- § 26A:30 The HRSA audit process
- § 26A:31 Audit reports and disputes
- § 26A:32 Changes in HRSA audit standards
- § 26A:33 Audits of manufacturers

## **X. 340B PROGRAM ADMINISTRATIVE DISPUTE RESOLUTION**

- § 26A:34 Regulatory history of the 340B program ADR process

## **XI. REIMBURSEMENT OF 340B PROGRAM DRUGS**

- § 26A:35 Generally
- § 26A:36 Medicare Part B payment for 340B hospital drugs
- § 26A:37 State 340B antidiscrimination laws

# **CHAPTER 27. MEDICAID FUNDAMENTALS**

- § 27:1 Introduction
- § 27:2 A brief history of medicaid
- § 27:3 Medicaid program overview
- § 27:4 Medicaid and COVID-19

## **I. THE STRUCTURE OF THE MEDICAID PROGRAM**

- § 27:5 Medicaid as a cooperative model
- § 27:6 If you've seen one Medicaid program . . . you've seen one Medicaid program
- § 27:7 Medicaid eligibility
- § 27:8 Eligibility groups
- § 27:9 Eligibility determinations
- § 27:10 Applying for Medicaid

## **II. MEDICAID BENEFITS**

- § 27:11 General overview of mandatory and optional benefits
- § 27:12 Limits on coverage
- § 27:13 Cost sharing
- § 27:14 Medicaid financing
- § 27:15 How do states fund their share of Medicaid expenditures?
- § 27:16 Medicaid managed care
- § 27:17 Medicaid expansion

TABLE OF CONTENTS

**III. THE FUTURE OF MEDICAID—A NEW ERA FOR  
THE FEDERAL-STATE MEDICAID  
PARTNERSHIP**

- § 27:18 State flexibility
- § 27:19 Section 1115 demonstration projects

**CHAPTER 28. REPAYMENTS AND SELF-  
DISCLOSURES**

- § 28:1 Introduction

**I. LEGAL AUTHORITIES LINKED TO REPAYMENT  
OBLIGATIONS OR FINANCIAL PENALTIES**

- § 28:2 Affordable Care Act and the 60 day repayment law  
for reporting and returning medicare and medicaid  
overpayments
- § 28:3 —Final rule addressing overpayments—Medicare  
Parts A and B
- § 28:4 — —Medicare Parts C and D
- § 28:5 —MA organization challenges to the rule
- § 28:6 —Comments
- § 28:7 False Claims Act (FCA)
- § 28:8 The Stark Law
- § 28:9 The Anti-Kickback Statute (AKS)
- § 28:10 Private payers
- § 28:11 Other authorities

**II. BENEFITS AND INCENTIVES TO SELF-  
DISCLOSE**

- § 28:12 Benefits—General
- § 28:13 Federal Sentencing Guidelines
- § 28:14 OIG policies encouraging self-disclosure
- § 28:15 Whistleblowers
- § 28:16 Prosecutorial discretion
- § 28:17 The Medicare Prescription Drug, Improvement, and  
Modernization Act of 2003

**III. THE RISKS OF SELF-DISCLOSURE**

- § 28:18 Considerations as to where to make a self-disclosure
- § 28:19 OIG Provider Self-Disclosure Protocol (SDP) and  
Stark Law Self-Referral Disclosure Protocol (SRDP)
- § 28:20 —When to use the OIG self-disclosure protocol
- § 28:21 —Format and content for disclosure to OIG
- § 28:22 —Internal investigation requirements
- § 28:23 —Potential for reduced penalties

- § 28:24 —OIG follow-up
- § 28:25 When to use the self-referral disclosure protocol
- § 28:26 —Format and content for self-referral disclosure
- § 28:27 —SRDP disclosure form
- § 28:28 —Physician information form
- § 28:29 —Financial analysis worksheet
- § 28:30 —Certification
- § 28:31 —Potential for reduced penalties
- § 28:32 —CMS follow-up
- § 28:33 Other self-disclosure protocols
- § 28:34 Self-disclosure guidance and best practices

## **CHAPTER 29. FALSE CLAIMS ACT FUNDAMENTALS**

- § 29:1 Introduction
- § 29:2 Overview of the FCA
- § 29:3 Key FCA considerations for health care entities
- § 29:4 Who is a “person”?
- § 29:5 What is “knowingly”?
- § 29:6 Deliberate ignorance
- § 29:7 Reckless disregard
- § 29:8 What is a “claim”?
- § 29:9 What is “causing” a claim to be submitted?
- § 29:10 What is “false” or “fraudulent”?
- § 29:11 Retention of overpayments and reverse false claims
- § 29:12 Use of statistical sampling to establish False Claims Act liability
- § 29:13 What is “material”?
- § 29:14 Express and implied false certification
- § 29:15 The *Escobar* decision
- § 29:16 Anti-kickback violations as false claims
- § 29:17 Penalties and damages
- § 29:18 *Qui tam* relators
- § 29:19 How is a *qui tam* action initiated?
- § 29:20 What happens if the government declines to intervene?
- § 29:21 Who can be a *qui tam* relator?
- § 29:22 Public disclosure bar
- § 29:23 Original source rule
- § 29:24 Pleading requirements for *qui tam* suits
- § 29:25 Retaliation
- § 29:26 Statute of limitations
- § 29:27 Relevant DOJ guidance regarding the False Claims Act
- § 29:28 The Yates Memo
- § 29:29 Cooperation credit

## TABLE OF CONTENTS

- § 29:30 The Brand Memo
- § 29:31 The Granston Memo
- § 29:32 Corporate compliance program guidance
- § 29:33 Inability-to-pay guidance

## **CHAPTER 29A. MEDICAL NECESSITY, CLAIMS, AND PAYMENT PROCESSES**

- § 29A:1 Introduction

### **I. KEY ELEMENTS OF MEDICAL NECESSITY**

- § 29A:2 Definition of medical necessity
- § 29A:3 Sources to determine medical necessity
- § 29A:4 —National coverage determinations
- § 29A:5 —Local coverage determinations
- § 29A:6 —Interpretive manuals
- § 29A:7 Physician supervision
- § 29A:8 Inpatient services
- § 29A:9 Medical records documentation
- § 29A:10 —Coding and billing accuracy
- § 29A:11 —Charge description master
- § 29A:12 —National Correct Coding Initiative
- § 29A:13 —Compliance policies and procedures on proper documentation and claims submission
- § 29A:14 —Compliance training and education on proper documentation and coding
- § 29A:15 Claims payment processes
- § 29A:16 —Waiver of copayments/deductibles
- § 29A:17 —Credit balances
- § 29A:18 —Medicare secondary payer documentation
- § 29A:19 Prospective payment system issues
- § 29A:20 —DRG Payment Window Rule
- § 29A:21 —Ambulatory payment classifications
- § 29A:22 —PPS transfer initiative
- § 29A:23 Notice of payment obligation
- § 29A:24 —Beneficiary Notices (MOON)
- § 29A:25 —Payment for non-covered services
- § 29A:26 Cost reports
- § 29A:27 CMS review processes
- § 29A:28 —CMS's 2017 Audit Strategy in 2017
- § 29A:29 OIG work plans and audits

### **II. THE FALSE CLAIMS ACT AND MEDICAL NECESSITY**

- § 29A:30 Theories of False Claims Act liability in medical necessity cases

- § 29A:31 —Provider defenses
- § 29A:32 —Medical necessity enforcement trends
- § 29A:33 —Operation LabScam
- § 29A:34 —Implantable cardioverter defibrillators
- § 29A:35 —Stents
- § 29A:36 —Proper patient status: short stay and observation cases
- § 29A:37 —Level of care and worthless services cases
- § 29A:38 —Criminal investigations and convictions based on medical necessity allegations

## **CHAPTER 29B. OVERPAYMENT INVESTIGATIONS, REFUNDS, AND FALSE CLAIMS ACT EXPOSURE**

- § 29B:1 Introduction
- § 29B:2 Overview of the Overpayment Statute and Final Rule
- § 29B:3 Before the Overpayment Statute
- § 29B:4 CMP liability
- § 29B:5 FCA liability
- § 29B:6 The Overpayment Statute
- § 29B:7 “Knowingly”
- § 29B:8 Intersection with the FCA
- § 29B:9 The Overpayment Rule
- § 29B:10 “Lookback Period”
- § 29B:11 “Identified”
- § 29B:12 “Reasonable Diligence”
- § 29B:13 “Credible Information”
- § 29B:14 Caught between a rock and a hard place
- § 29B:15 Proposed rule change: definition of “Identified”
- § 29B:16 More Interpretive Challenges: What *is* an “Overpayment”?
- § 29B:17 Conditions of participation versus conditions of payment
- § 29B:18 Relevance of *Escobar*
- § 29B:19 Post-*Escobar* materiality cases
- § 29B:20 Conclusion

## **CHAPTER 30. THE BASICS OF THE STARK AND ANTI-KICKBACK LAWS**

### **I. INTRODUCTION**

- § 30:1 Generally

### **II. THE ANTI-KICKBACK STATUTE**

- § 30:2 Overview

## TABLE OF CONTENTS

- § 30:3 Safe harbors under the anti-kickback statute
- § 30:4 Interpreting the anti-kickback statute

### **III. PHYSICIAN SELF-REFERRAL LAWS (STARK)**

- § 30:5 Overview
- § 30:6 History

### **IV. ESSENTIAL ELEMENTS OF STARK DEFINED**

- § 30:7 Statement of the prohibition
- § 30:8 “Financial relationship”
- § 30:9 “Referral”
- § 30:10 Designated Health Services (DHS)
- § 30:11 Self-reporting
- § 30:12 Sanctions

### **V. EXCEPTIONS TO STARK**

- § 30:13 Exceptions to ownership and compensation arrangements prohibition
- § 30:14 Exceptions to ownership or investment prohibition
- § 30:15 Exceptions to compensation arrangements prohibition
- § 30:16 “Volume or value of referrals”
- § 30:17 Written arrangement requirement
- § 30:18 Minimum term requirement
- § 30:19 Signature requirement
- § 30:20 Physicians deemed to “stand in the shoes”
- § 30:21 Accountable Care Organizations (ACOs)

## **CHAPTER 30A. FINAL 2020 RULES MODERNIZING AND CLARIFYING THE FEDERAL STARK AND ANTI-KICKBACK LAWS**

### **I. INTRODUCTION**

- § 30A:1 Generally

### **II. OVERVIEW OF THE FINAL RULES**

- § 30A:2 Generally

### **III. TERMINOLOGY**

- § 30A:3 Generally
- § 30A:4 Value-based enterprise participant
- § 30A:5 Value-based enterprise

- § 30A:6 Value-based arrangement
- § 30A:7 Value-based activities
- § 30A:8 Value-based purpose
- § 30A:9 Target patient population
- § 30A:10 Coordinating and managing care

#### **IV. STARK FINAL VALUE-BASED ARRANGEMENT EXCEPTIONS**

- § 30A:11 Generally
- § 30A:12 Requirements applicable to all three of the value-based exceptions
- § 30A:13 Full financial risk exception (42 CFR § 411.357(aa)(1))
- § 30A:14 Meaningful downside financial risk exception (42 CFR § 411.357(aa)(2))
- § 30A:15 Value-based arrangements exception (42 CFR § 411.357(aa)(3))
- § 30A:16 VBE profit distributions in stark group practice (42 CFR § 411.352(i))

#### **V. AKS VALUE-BASED SAFE HARBORS**

- § 30A:17 Generally
- § 30A:18 Full financial risk safe harbor (42 CFR § 1001.952(gg))
- § 30A:19 Substantial downside risk safe harbor (42 CFR § 1001.952(ff))
- § 30A:20 Care coordination safe harbor (42 CFR § 1001.952(ee))

#### **VI. OTHER VALUE-BASED RELATED SAFE HARBORS**

- § 30A:21 Generally
- § 30A:22 Patient engagement and support safe harbor (42 CFR § 1001.952(hh))
- § 30A:23 CMS-sponsored innovative payment models safe harbor (42 CFR § 1001.952(ii))
- § 30A:24 Outcomes-based payment safe harbor (42 CFR § 1001.952(d)(2)–(3))

#### **VII. ENABLING TECHNOLOGY INFRASTRUCTURE IMPROVEMENTS**

- § 30A:25 Generally
- § 30A:26 Cybersecurity technology and related services (42 CFR § 411.357(bb) and 42 CFR § 1001.952(jj))
- § 30A:27 Electronic health records items and services (42 CFR § 411.357(w) and 42 CFR § 1001.952(y))

TABLE OF CONTENTS

- § 30A:28 Beneficiary inducements CMP exception for telehealth technologies for in-home dialysis patients (42 CFR § 1003.110)

**VIII. MODERNIZING STARK AND AKS: NEW RULES, DEFINITIONS AND CLARIFICATIONS**

- § 30A:29 Generally

**IX. STARK FINAL RULE: NEW DEFINITIONS, EXCEPTIONS, AND CLARIFICATIONS**

- § 30A:30 Clarifying commercially reasonable, volume or value, and fair market value (42 CFR § 411.351 and 42 CFR § 411.354(d)(5)&(6))
- § 30A:31 Narrowing the designated health services definition (42 CFR § 411.351)
- § 30A:32 Narrowing of the indirect compensation arrangement definition (42 CFR § 411.357(aa) and 42 CFR § 411.354(c))
- § 30A:33 Clarifying the definition of isolated transaction (42 CFR § 411.351 and 42 CFR § 411.357(f))
- § 30A:34 Narrowing the ownership & investment interest definition (42 CFR § 411.354(b))
- § 30A:35 Adding flexibility with new limited remuneration exception and leeway to remedy stark violations and meet writing and signature requirements (42 CFR § 411.357(z), 42 CFR § 411.353(h) and 42 CFR § 411.354(e))
- § 30A:36 Modifications to the set in advance requirement (42 CFR § 411.354(d)(1))
- § 30A:37 Updated special rules for group practices (42 CFR § 411.352(i))
- § 30A:38 Directed referrals and protecting patient rights (42 CFR § 411.354(d)(4))
- § 30A:39 CMS *Does Not* breathe life into the remuneration unrelated to the provision of DHS exception (42 CFR § 411.357(g))
- § 30A:40 CMS decouples stark, AKS and federal and state laws or regulations governing billing or claims submission
- § 30A:41 Eliminating overly prescriptive and impractical period of disallowance rules (42 CFR § 411.353(c)(1))
- § 30A:42 Electronic signatures (42 CFR § 411.354(e)(3))
- § 30A:43 Writing and signature requirements for certain physician recruitment arrangements (42 CFR § 411.357(e))

## **X. FINAL AKS RULE: NEW AND EXPANDED SAFE HARBORS**

- § 30A:44 AKS personal services and management contracts (42 CFR § 1001.952(d)(1))
- § 30A:45 AKS warranties safe harbor (42 CFR § 1001.952(g))
- § 30A:46 AKS local transportation safe harbor (42 CFR § 1001.952(bb))
- § 30A:47 AKS ACO beneficiary incentive program safe harbor (42 CFR § 1001.952(kk))

## **XI. AKS: PHARMACEUTICAL DISCOUNTS AND PHARMACY BENEFIT MANAGER SERVICE FEES**

- § 30A:48 Generally
- § 30A:49 Discounts safe harbor (42 CFR § 1001.952(h))
- § 30A:50 Point-of-sale reductions in price for prescription pharmaceutical products (42 CFR § 1001.952(cc))
- § 30A:51 PBM service fees (42 CFR § 1001.952(dd))

# **CHAPTER 31. THE LEGAL BASICS OF VALUE BASED CARE**

## **I. INTRODUCTION**

- § 31:1 Generally

## **II. HISTORICAL OVERVIEW**

- § 31:2 Generally
- § 31:3 Alternative payment models
- § 31:4 Value-based payment models
- § 31:5 Regulatory changes and the “Sprint to Coordinated Care”

## **III. OVERVIEW OF KEY LEGAL ISSUES**

- § 31:6 Generally
- § 31:7 Basic fraud and abuse requirements
- § 31:8 Anti-kickback statute
- § 31:9 Stark law
- § 31:10 Program-specific waivers for alternative payment models

## **IV. THE CURRENT ENVIRONMENT**

- § 31:11 Generally
- § 31:12 Medicare ACOs

TABLE OF CONTENTS

- § 31:13 BPCI advanced (BPCI-A)
- § 31:14 Other CMMI models

**V. BACKDROP: ADVANCED APMS AND MACRA**

- § 31:15 Generally

**VI. CURRENT AREAS OF FOCUS**

- § 31:16 Generally
- § 31:17 Focus on post-acute care—IMPACT Act
- § 31:18 SNF value based purchasing requirements
- § 31:19 Value-based contracting in medicare advantage and commercial contracts

**VII. THE FUTURE OF VALUE-BASED PAYMENTS**

- § 31:20 Generally

**CHAPTER 31A. NAVIGATING VALUE-BASED AND RISK ARRANGEMENTS**

**I. INTRODUCTION**

- § 31A:1 Generally

**II. VALUE-BASED TERMINOLOGY**

- § 31A:2 Value-based terminology
- § 31A:3 Value-based enterprise (VBE) participant
- § 31A:4 Value-based enterprise (VBE)
- § 31A:5 Value-based arrangement
- § 31A:6 Value-based activities
- § 31A:7 Value-based purpose
- § 31A:8 Target patient population
- § 31A:9 Coordinating and managing care

**III. STARK FINAL VALUE-BASED ARRANGEMENT EXCEPTIONS**

- § 31A:10 Stark final value-based arrangement exceptions
- § 31A:11 Requirements applicable to all three of the value-based exceptions
- § 31A:12 Full financial risk exception (42 CFR § 411.357(aa)(1))
- § 31A:13 Meaningful downside financial risk exception (42 CFR § 411.357(aa)(2))
- § 31A:14 Value-based arrangements exception (42 CFR § 411.357(aa)(3))

- § 31A:15 Other CMS updates to facilitate the transition to value-based health care

#### **IV. AKS VALUE -BASED ARRANGEMENTS SAFE HARBORS**

- § 31A:16 AKS value-based arrangements safe harbors
- § 31A:17 Common requirements in value-based safe harbors
- § 31A:18 Full financial risk safe harbor (42 CFR § 1001.952(gg))
- § 31A:19 Substantial downside risk safe harbor (42 CFR § 1001.952(ff))
- § 31A:20 Care coordination safe harbor (42 CFR § 1001.952(ee))

#### **V. OTHER PROTECTIONS FOR VALUE-BASED CARE**

- § 31A:21 Other protections for value-based care
- § 31A:22 Patient engagement and support safe harbor (42 CFR § 1001.952(hh))
- § 31A:23 CMS-Sponsored innovative payment models safe harbor (42 CFR § 1001.952(ii))
- § 31A:24 Outcomes-based payment safe harbor (42 CFR § 1001.952(d)(2)–(3))
- § 31A:25 AKS ACO beneficiary incentive program safe harbor (42 CFR § 1001.952(kk))

#### **VI. OTHER SAFE HARBORS AND EXCEPTIONS POTENTIALLY IMPORTANT TO VALUE-BASED ARRANGEMENTS**

- § 31A:26 Managed care-related exceptions and safe harbors
- § 31A:27 Technology-related safe harbors

### **PART IV. TRANSACTIONS**

#### **CHAPTER 32. THE FUNDAMENTALS OF A HEALTH CARE TRANSACTION**

##### **I. INTRODUCTION**

- § 32:1 Introduction
- § 32:2 Initiating a deal and choosing a structure

##### **II. BRIEF EXPLANATION OF TRANSACTION STRUCTURES**

- § 32:3 Affiliation

TABLE OF CONTENTS

- § 32:4 Collaboration
- § 32:5 Management services
- § 32:6 Joint venture
- § 32:7 Partial asset sale
- § 32:8 Partial sale of stock
- § 32:9 Acquisition transaction
- § 32:10 Merger

**III. STAGES OF A DEAL**

- § 32:11 Letter of intent/confidentiality agreement
- § 32:12 Due diligence
- § 32:13 Closing checklist

**IV. PRIMARY TRANSACTION AGREEMENT**

- § 32:14 Primary transaction agreement
- § 32:15 Structure and definitions
- § 32:16 Financial matters
- § 32:17 Representations and warranties
- § 32:18 Covenants
- § 32:19 Closing conditions
- § 32:20 Indemnification

**V. DISCLOSURE SCHEDULES**

- § 32:21 Disclosure schedules

**VI. EMPLOYMENT, CONSULTANT OR DIRECTOR AGREEMENTS**

- § 32:22 Employment, consultant or director agreements

**VII. GETTING TO CLOSING**

- § 32:23 Getting to closing

**VIII. POST-CLOSING MATTERS**

- § 32:24 Post-closing matters

**CHAPTER 32A. HEALTH CARE ANTITRUST LAW**

**I. INTRODUCTION TO ANTITRUST LAW**

- § 32A:1 Antitrust in the health care industry

**II. PURPOSE OF THE ANTITRUST LAWS**

- § 32A:2 Competition and consumer protection

**III. ANTITRUST ANALYSIS**

- § 32A:3 Antitrust analysis framework
- § 32A:4 Relevant-Market definition
- § 32A:5 Market share, market concentration, and effect on competition

**IV. ANALYSIS OF THE SUBSTANTIVE ANTITRUST STATUTES**

- § 32A:6 Basic antitrust statutes
- § 32A:7 Section 1 of the Sherman Act
- § 32A:8 The agreement
- § 32A:9 Unreasonable restraint on competition
- § 32A:10 Agreements with potential Section 1 ramifications
- § 32A:11 Horizontal price-fixing agreements
- § 32A:12 Horizontal wage-fixing and no-poaching agreements
- § 32A:13 Horizontal agreements to exchange pricing information
- § 32A:14 Horizontal market-allocation agreements
- § 32A:15 Horizontal concerted refusals to deal or group boycotts
- § 32A:16 Tying agreements
- § 32A:17 Exclusive dealing agreements
- § 32A:18 Section 2 of the sherman Act
- § 32A:19 Monopolization
- § 32A:20 Attempted monopolization
- § 32A:21 Section 7 of the Clayton Act
- § 32A:22 Definition of the relevant product market
- § 32A:23 Definition of the relevant geographic market
- § 32A:24 Identification of competitors in the relevant market
- § 32A:25 Calculation of each competitor's market share
- § 32A:26 Calculation of the merging firms' post-merger market share, the level of market concentration, and the increase in market concentration resulting from the merger
- § 32A:27 Examination of factors that might indicate that post-merger market share or market concentration statistics are misleading
- § 32A:28 State Pre-Merger notification laws
- § 32A:29 The federal trade commission Act

**V. EXEMPTIONS, IMMUNITIES, AND SCOPE OF COVERAGE**

- § 32A:30 When antitrust laws are inapplicable
- § 32A:31 Nonprofit entities
- § 32A:32 Federal governmental immunity

## TABLE OF CONTENTS

- § 32A:33 State action exemption
- § 32A:34 Solicitation of governmental action
- § 32A:35 Local government antitrust Act
- § 32A:36 Business of insurance
- § 32A:37 Labor unions
- § 32A:38 Health care quality improvement Act

## **VI. GOVERNMENT ENFORCEMENT**

- § 32A:39 The antitrust division
- § 32A:40 The federal trade commission
- § 32A:41 State attorneys general

## **VII. PRIVATE ENFORCEMENT**

- § 32A:42 Standing
- § 32A:43 Causation
- § 32A:44 Antitrust injury
- § 32A:45 Limitations on antitrust standing
- § 32A:46 Damages

## **VIII. CONCLUSION**

- § 32A:47 Specific applications of antitrust law in the health care sector

## **CHAPTER 32B. PRIVATE EQUITY INVESTMENT IN HEALTH CARE ENTERPRISES**

- § 32B:1 Introduction
- § 32B:2 Considerations for transaction structure and corporate practice of medicine
- § 32B:3 The management services organization: A compliant alternative
- § 32B:4 Due diligence
- § 32B:5 Corporate
- § 32B:6 Financial/Debt
- § 32B:7 Payer mix and reimbursement
- § 32B:8 Contracts and arrangements
- § 32B:9 Litigation and health care compliance
- § 32B:10 Regulatory
- § 32B:11 Data privacy and security
- § 32B:12 Employment matters
- § 32B:13 Real estate
- § 32B:14 Intellectual property
- § 32B:15 Environmental
- § 32B:16 Insurance

- § 32B:17 Reverse due diligence
- § 32B:18 Negotiating the definitive agreements
- § 32B:19 Conclusion

## **CHAPTER 33. HEALTH CARE BRANDING**

- § 33:1 Introduction/brand for equity deals
- § 33:2 Variables affecting legal structure and risk
- § 33:3 Possible value measures and regulatory risks—  
Market, income and cost methods
- § 33:4 Performance metrics
- § 33:5 Dealing with the stark/anti-kickback risk
- § 33:6 Potential tort liability
- § 33:7 Brand use conditions
- § 33:8 Common stark and anti-kickback considerations
- § 33:9 “Takes into account”
- § 33:10 Use of referral data—Compliance-based uses
- § 33:11 —Determining investors
- § 33:12 Use of safeguards
- § 33:13 Federal tax considerations—Unrelated business  
income
- § 33:14 Management contracts for bond-financed facilities
- § 33:15 Inurement and private benefit
- § 33:16 Nonprofit/for-profit joint ventures

## **CHAPTER 34. DISTRESSED ACQUISITIONS AND DIVESTITURES**

- § 34:1 Introduction
- § 34:2 Market snapshot of healthcare bankruptcies
- § 34:3 Leading indicators of financial distress
- § 34:4 Covenant defaults
- § 34:5 Deteriorating liquidity
- § 34:6 Negative operating margins
- § 34:7 Related party receivables and/or payables
- § 34:8 Regulatory issues
- § 34:9 Disruption of IT systems
- § 34:10 Sale process: Options and considerations
- § 34:11 Due diligence considerations
- § 34:12 Ability to deliver title
- § 34:13 Price of transaction based on unique risks
- § 34:14 No indemnity from seller
- § 34:15 Timing considerations
- § 34:16 Distressed transaction terms and jargon
- § 34:17 Stalking horse auctions and private sales

TABLE OF CONTENTS

**CHAPTER 35. INTRODUCTION TO TAX-EXEMPT HEALTH CARE ORGANIZATIONS**

**I. INTRODUCTION TO THE BASICS OF SECTION 501(C)(3) STATUS**

§ 35:1 Introduction

**II. QUALIFICATION AS 501(C)(3) ORGANIZATION**

§ 35:2 Overview of 501(C)(3) qualifications

§ 35:3 Private benefit

§ 35:4 Private inurement

§ 35:5 Political campaign activities

**III. TYPES OF EXEMPT HEALTH CARE ORGANIZATIONS**

§ 35:6 Hospitals

§ 35:7 Community Health Needs Assessment (CHNA)

§ 35:8 Financial assistance and emergency medical care policies

§ 35:9 Limitations on charges to patients eligible for financial assistance

§ 35:10 Billing and collection requirements

§ 35:11 Home health agencies

§ 35:12 Homes for the aged/assisted living centers

§ 35:13 Physician practice plans

§ 35:14 Integrated delivery systems

§ 35:15 Medical research organizations

§ 35:16 HMOs

§ 35:17 Information technology organizations

§ 35:18 Accountable care organizations

**IV. PUBLIC CHARITY VS PRIVATE FOUNDATION STATUS**

§ 35:19 Private foundation status

§ 35:20 Code Section 509(a)(1) organizations

§ 35:21 Code Sections 509(a)(1) and 170(b)(1)(A)(vi)—Publicly supported organizations

§ 35:22 Code Section 509(a)(2) organization—Service organizations

§ 35:23 Code Section 509(a)(3) organization—Supporting organization

**V. INTERMEDIATE SANCTIONS**

§ 35:24 Overview of intermediate sanctions

- § 35:25 Imposition of taxes
- § 35:26 Excess benefit transactions
- § 35:27 Disqualified persons
- § 35:28 Rebuttable presumption of reasonableness

## **VI. TAX-EXEMPT FINANCING**

- § 35:29 Overview of tax-exempt financing
- § 35:30 Section 501(c)(3) financing
- § 35:31 Arbitrage

## **VII. CODE SECTION 501(C)(4) QUALIFICATION**

- § 35:32 Overview of Code Section 501(c)(4)

## **VIII. UNRELATED BUSINESS INCOME TAX (UBIT)**

- § 35:33 Legal overview of UBIT
- § 35:34 Modifications and exclusions
- § 35:35 Application of UBIT rules to common health care income-producing activities

# **CHAPTER 35A. AUDIT RISKS FOR NONPROFIT HEALTH CARE ORGANIZATIONS\***

## **I. INTRODUCTION**

- § 35A:1 Overview of Audit Risks

## **II. UNRELATED BUSINESS INCOME TAX (UBIT)**

- § 35A:2 Definition of UBIT
- § 35A:3 Patient/Non-Patient test for whether laboratory services, pharmacy and gift shop sales are UBIT
- § 35A:4 Debt financed income
- § 35A:5 Offsetting UBI with siloing rules
- § 35A:6 Joint ventures
- § 35A:7 Management services

## **III. WORKER CLASSIFICATION**

- § 35A:8 Common Test Law Control
- § 35A:9 Compliance Red Flags

## **IV. IRC § 501(R) COMPLIANCE**

- § 35A:10 Section 501(r) Requirements
- § 35A:11 Compliance strategies

TABLE OF CONTENTS

**V. COMMUNITY BENEFIT**

- § 35A:12 Community Benefit Requirements
- § 35A:13 Community benefit compliance tips

**VI. EXCESSIVE COMPENSATION**

- § 35A:14 Areas of Risk and Avoidance Strategies

**VII. IRC § 4960 EXCISE TAXES**

- § 35A:15 Section 4960 Requirements

**VIII. LOANS TO DIRECTORS AND OFFICERS**

- § 35A:16 Risks Associated with Loans

**IX. POLITICAL ACTIVITIES**

- § 35A:17 Scope of the Prohibition on Political Activities

**X. ACCOUNTABLE CARE ORGANIZATIONS/  
CLINICALLY INTEGRATED NETWORKS (CINS)**

- § 35A:18 Risks Associated with Participation in an ACO

**XI. OFFSHORE INVESTMENTS**

- § 35A:19 How Offshore Investments Can Trigger Audits

**XII. CONCLUSION**

- § 35A:20 IRS Scrutiny is Expanding

**CHAPTER 36. INTERNATIONAL HEALTH  
CARE TRANSACTIONS**

**I. INTRODUCTION**

- § 36:1 Generally
- § 36:2 Cultural and language issues
- § 36:3 Culture and negotiating style
- § 36:4 Importance of local counsel

**II. APPLICABLE LAWS**

- § 36:5 Generally
- § 36:6 Foreign Corrupt Practices Act
- § 36:7 Accounting and anti-bribery provisions
- § 36:8 Other anti-bribery laws
- § 36:9 UK Bribery Act

- § 36:10 Laws restricting certain activities—Economic sanctions, embargoes, anti-terrorism (often referred to as “export control”)
- § 36:11 The New York arbitration convention

### **III. DUE DILIGENCE**

- § 36:12 Due diligence generally
- § 36:13 Bribery-related diligence
- § 36:14 Corruption perception index
- § 36:15 Background checks
- § 36:16 Due diligence questionnaire

### **IV. GENERAL CONTRACT PROVISIONS**

- § 36:17 Generally
- § 36:18 Currency
- § 36:19 Taxes
- § 36:20 Language
- § 36:21 Compliance with laws
- § 36:22 Arbitration

### **V. SAMPLE AFFILIATION STRUCTURES & PRACTICAL ISSUES**

- § 36:23 Transaction structures—Ability to do business in the jurisdiction
- § 36:24 Multiple-party transactions
- § 36:25 Governance and control
- § 36:26 Remote relationships (telehealth and consultations)
- § 36:27 Process: from conversations to the definitive agreements

# Table of Contents

## **PART V. LEGAL CONCERNS IN SPECIFIC HEALTH CARE DELIVERY SETTINGS**

### **CHAPTER 37. LONG TERM CARE AND MEDICARE/MEDICAID REIMBURSEMENT**

#### **I. MEDICAID FUNDAMENTALS**

- § 37:1 Introduction
- § 37:2 Medicaid spending
- § 37:3 Delivery systems and payment models
- § 37:4 Medicaid reimbursement and financing
- § 37:5 Changes in Medicaid since the Affordable Care Act
- § 37:6 Medicaid changes in 2019

#### **II. MEDICARE FUNDAMENTALS**

- § 37:7 Introduction
- § 37:8 Medicare spending
- § 37:9 Medicare Part A—Eligibility
- § 37:10 —Current reimbursement models
- § 37:11 SNF Medicare Part A—Proposed reimbursement system
- § 37:12 Medicare Part A—The impact of quality
- § 37:13 Medicare Part B—Eligibility and coverage
- § 37:14 —Payments to providers
- § 37:15 Merit Based Incentive Payments System (MIPS)
- § 37:16 Advanced Alternative Payment Models (APMs)
- § 37:17 2019 updates and changes to the QPP
- § 37:18 Medicare Part C
- § 37:19 —Coverage
- § 37:20 Part C and skilled nursing facilities
- § 37:21 2019 Medicare Advantage changes
- § 37:22 Medicare Part D

### **CHAPTER 38. PHYSICIAN PRACTICE CONCERNS**

#### **I. INTERACTION OF PHYSICIANS AND LAWYERS**

- § 38:1 Generally

- § 38:2 The role of malpractice anxiety
- § 38:3 Physician attitudes
- § 38:4 Attorney socialization

## **II. SPECIAL PROBLEMS FOR PHYSICIANS IN THE HEALTH LAW BUSINESS SETTING**

- § 38:5 Mixed messages and conflicting themes
- § 38:6 —Competition vs. antikickback and antitrust
- § 38:7 Mixed messages and conflicting themes—  
Confidentiality, peer review protection, data  
dissemination and transparency
- § 38:8 Mixed messages and conflicting themes—Legal  
discontinuity
- § 38:9 The physician's electronic reality
- § 38:10 The rules keep changing
- § 38:11 Intention is often irrelevant
- § 38:12 Clinical judgment is increasingly linked to business  
issues

## **III. PROBLEMS FOR THE LAWYER REPRESENTING THE PHYSICIAN**

- § 38:13 The technicalities in the law
- § 38:14 There is no answer
- § 38:15 The systems are linked
- § 38:16 Selective enforcement

## **IV. TYPICAL PROBLEM AREAS**

- § 38:17 Generally
- § 38:18 Fraud and abuse
- § 38:19 Reimbursement
- § 38:20 Relating in groups
- § 38:21 Relating to managed care entities and hospitals
- § 38:22 Relating to other professionals
- § 38:23 Not recognizing the serious problem
- § 38:24 Conclusion

# **CHAPTER 38A. PHYSICIAN PRACTICE DISSOLUTION**

## **I. INTRODUCTION**

- § 38A:1 Medical practice departures and breakups

## **II. CONFLICTS OF INTEREST FOR THE PRACTICE'S ATTORNEY**

- § 38A:2 How conflicts of interest arise

TABLE OF CONTENTS

**III. UNDERSTANDING THE PARTIES' GOALS AND MOTIVATIONS**

§ 38A:3 Analysis

**IV. PHYSICIAN PRACTICE DISSOLUTION: KEY STEPS**

§ 38A:4 Build a team

§ 38A:5 Collect documentation

§ 38A:6 Examine the physician's fiduciary duty and duty of loyalty

§ 38A:7 Review the office lease

§ 38A:8 Evaluate bank debt

**V. HOSPITAL RECRUITING AGREEMENT ISSUES**

§ 38A:9 Purpose of the agreement

§ 38A:10 Specific concerns with recruitment arrangements

**VI. NOTIFICATION OF PATIENTS**

§ 38A:11 Legal issues

**VII. PATIENT MEDICAL RECORDS**

§ 38A:12 Practice dissolution issues

**VIII. BILLING AND COLLECTION OF ACCOUNTS RECEIVABLE**

§ 38A:13 Completion of outstanding accounts

**IX. EMPLOYEE BENEFITS**

§ 38A:14 Personnel and benefits issues

§ 38A:15 Health insurance

§ 38A:16 Life and disability insurance

§ 38A:17 Retirement plan benefits

§ 38A:18 Professional liability insurance

§ 38A:19 Paid time off and reimbursement of business expenses

**X. NOTIFICATION ISSUES**

§ 38A:20 Government and other parties

**XI. AGREEMENTS WITH INDIVIDUAL PHYSICIANS**

§ 38A:21 Enforcement of restrictive covenants, confidentiality and trade secrets

## **XII. OTHER BUSINESS VENTURES**

§ 38A:22 Termination or continuation

## **XIII. DIVISION OF PRACTICE ASSETS**

§ 38A:23 Potential for disagreement

§ 38A:24 Inventory the practice's assets

§ 38A:25 Issues with specific types of assets

## **XIV. OTHER REGULATORY CONCERNS**

§ 38A:26 Tax and fraud and abuse issues

## **XV. POST-DISSOLUTION ISSUES**

§ 38A:27 Post-Departure liabilities

§ 38A:28 Indemnification and guarantees

# **CHAPTER 39. CONSTRUCTION CONTRACTS IN POST-ACUTE CARE AND SENIOR HOUSING**

## **I. INTRODUCTION**

§ 39:1 Introduction

## **II. GENERAL OVERVIEW OF CONSTRUCTION PROJECTS AND CONTRACTS**

§ 39:2 General Overview

§ 39:3 Parties and Players Relevant to a Construction Project

§ 39:4 Construction Project Delivery Systems

§ 39:5 Common Construction and Design Contracts

## **III. RISKS ASSOCIATED WITH CONSTRUCTION IN THE POST-ACUTE CARE AND SENIOR LIVING INDUSTRY**

§ 39:6 Risks

§ 39:7 Dual Permitting

§ 39:8 Fair Housing Act

§ 39:9 Special Considerations for Memory Care

§ 39:10 Confidentiality and HIPAA

§ 39:11 Vaccination Requirements

## **IV. DELAYS, LIQUIDATED DAMAGES, WAIVERS OF CONSEQUENTIAL DAMAGES, AND LIMITATIONS OF LIABILITY**

§ 39:12 Construction Delays

## TABLE OF CONTENTS

- § 39:13 Owner's Damages: Actual Damages Due to Delay
- § 39:14 Waivers of Consequential Damages
- § 39:15 Liquidated Damages
- § 39:16 Limitations or Caps on Delay Damages
- § 39:17 Consequential Damage Waivers in Design  
Professional Contracts
- § 39:18 Limitations of Liability

## **V. CHOICE OF LAW/CHOICE OF FORUM**

- § 39:19 Choice of Law/Choice of Forum

## **VI. INDEMNITY**

- § 39:20 Indemnity
- § 39:21 What is an Anti-Indemnity Statute?

## **VII. STATE SPECIFIC LAWS**

- § 39:22 State Specific Laws

# **CHAPTER 40. AN INTRODUCTION TO HOME HEALTH AND HOSPICE**

## **I. HOME HEALTH AGENCIES**

- § 40:1 Overview of Home Health Agencies
- § 40:2 Medicare reimbursement for HHAs
- § 40:3 Episodic care
- § 40:4 Case mix adjustment
- § 40:5 Outlier payments
- § 40:6 Low-utilization payments (LUPA)
- § 40:7 Partial episode payment adjustment (PEP)
- § 40:8 Medicaid HHAs
- § 40:9 State licensure and CON
- § 40:10 Conditions of Coverage for the Medicare Home  
Health Benefit
- § 40:11 Plan of care requirements
- § 40:12 Home bound status
- § 40:13 Physician certification
- § 40:14 Timing
- § 40:15 Identification of physician
- § 40:16 Re-certifications
- § 40:17 Oversight of unskilled services
- § 40:18 Face-to-face encounters

## **II. CONDITIONS OF PARTICIPATION FOR HHAS**

- § 40:19 Generally

- § 40:20 Home Health Quality Reporting Program
- § 40:21 Home Health Value-Based Purchasing (HHVBP) Model
- § 40:22 New HHA discharge planning proposal

### **III. FRAUD AND ABUSE, COMPLIANCE PROGRAM GUIDANCE AND THE OIG'S 2016 WORK PLAN FOR HHAS**

- § 40:23 Scope of enforcement
- § 40:24 2016 OIG Work Plan
- § 40:25 Moratorium on HHA applications
- § 40:26 36 month rule

### **IV. HOSPICES**

- § 40:27 Overview and definitions
- § 40:28 Election of hospice benefit
- § 40:29 Certificate of terminal illness
- § 40:30 MHB conditions of payment

### **V. HOSPICE SERVICES**

- § 40:31 Generally
- § 40:32 Core services
- § 40:33 Non-core services
- § 40:34 Levels of hospice care
- § 40:35 Routine home care (RHC)
- § 40:36 Inpatient respite care (Respite)
- § 40:37 General inpatient care (GIP)
- § 40:38 Continuous home care (CHC)

### **VI. REIMBURSEMENT**

- § 40:39 Medicare Part A
- § 40:40 Medicare Part B
- § 40:41 Medicaid

### **VII. STATE LICENSURE AND CERTIFICATE OF NEED**

- § 40:42 Generally
- § 40:43 Certificate of Need (CON)

### **VIII. FRAUD AND ABUSE CONCERNS**

- § 40:44 Areas of enforcement
- § 40:45 SHF/hospice relationships
- § 40:46 Recent OIG Work Plans

TABLE OF CONTENTS

§ 40:47 The concept of “relatedness”

**CHAPTER 41. LABORATORY COMPLIANCE ISSUES**

**I. INTRODUCTION**

§ 41:1 Introduction

**II. RELEVANT LAWS AND REGULATIONS**

- § 41:2 Federal laws and regulations—Anti-Kickback Statute
- § 41:3 —The Stark law
- § 41:4 —The False Claims Act
- § 41:5 —Civil Monetary Penalties Law
- § 41:6 —“Substantially in excess” prohibition
- § 41:7 —Criminal Health Care Fraud
- § 41:8 State laws and regulations

**III. FEDERAL AGENCY GUIDANCE**

- § 41:9 OIG compliance guidance
- § 41:10 Special Fraud Alerts
- § 41:11 Special Fraud Alert—December 19, 1994
- § 41:12 —June 25, 2014
- § 41:13 OIG advisory opinions
- § 41:14 Advisory opinion 99-13
- § 41:15 Advisory opinion 05-08
- § 41:16 Advisory opinion 15-04
- § 41:17 CMS advisory opinions

**IV. RECENT CASES AND SETTLEMENTS**

- § 41:18 Biodiagnostics Laboratory Services
- § 41:19 Health Diagnostic Laboratory (HDL)
- § 41:20 Family Dermatology
- § 41:21 CIGNA v. HDL

**V. HOT TOPICS IN LABORATORY COMPLIANCE**

- § 41:22 Making payments to physicians
- § 41:23 Placing personnel in physician offices
- § 41:24 Renting space from referral sources
- § 41:25 Providing supplies/equipment to clients
- § 41:26 Structuring client billing arrangements
- § 41:27 Offering waivers/discounts to patients

**VI. CONCLUSION**

§ 41:28 Conclusion

## **CHAPTER 42. REGULATORY AND LEGISLATIVE ISSUES IN ASSISTED LIVING**

### **I. INTRODUCTION**

§ 42:1 Introduction

### **II. CURRENT REGULATORY FRAMEWORK FOR ASSISTED LIVING**

§ 42:2 Overview

§ 42:3 Outlook for federal regulation of assisted living

§ 42:4 Regulatory outlook

§ 42:5 State licensure trends

### **III. HOT TOPICS FOR ASSISTED LIVING COUNSEL**

§ 42:6 Hot topics for assisted living counsel

§ 42:7 Licensure

§ 42:8 Emergency preparedness

§ 42:9 Cybersecurity/privacy/data security

§ 42:10 Quality of care issues

§ 42:11 Resident consent issues (sexual activity and dementia)

## **CHAPTER 43. FRANCHISING IN HEALTH CARE DELIVERY**

### **I. INTRODUCTION**

§ 43:1 The growth of franchising

§ 43:2 Franchising in health care

### **II. WHAT IS FRANCHISE LAW?**

§ 43:3 General concept

§ 43:4 Legal implications

§ 43:5 Advantages of the franchise business model

§ 43:6 Disadvantages of the franchise business model

### **III. HEALTH LAW ISSUES THAT IMPACT THE FRANCHISE ARRANGEMENT**

§ 43:7 Overview

§ 43:8 Corporate practice of medicine (CPM)

§ 43:9 Business organization rules

§ 43:10 Licensure and scope of practice

TABLE OF CONTENTS

§ 43:11 Advertising and marketing

**IV. FEDERAL AND STATE PRIVACY**

§ 43:12 Overview

§ 43:13 HIPAA

§ 43:14 Application of HIPAA

§ 43:15 Health franchises as covered entities

§ 43:16 Business associates in health franchises

§ 43:17 State privacy law

**V. PARTICIPATION IN GOVERNMENT HEALTH CARE PROGRAMS**

§ 43:18 Overview

**VI. PARTICIPATION WITH COMMERCIAL INSURANCE PLANS**

§ 43:19 Overview

**VII. FEDERAL ANTI-KICKBACK STATUTE**

§ 43:20 Overview

§ 43:21 Application of the AKS to health care franchises

§ 43:22 State anti-kickback statutes and fee splitting

**VIII. THE STARK LAW**

§ 43:23 Overview

**IX. SPECIFIC FRANCHISING ISSUES**

§ 43:24 The accidental franchise

§ 43:25 Franchisor's vicarious liability for franchisee

§ 43:26 Franchise registration and disclosure

§ 43:27 Franchise relationship laws

§ 43:28 Business opportunity laws

**X. AGREEMENTS NEEDED TO CREATE A FRANCHISE**

§ 43:29 Overview

§ 43:30 CPM terms

§ 43:31 Federal anti-kickback statute and fee splitting laws terms

§ 43:32 Federal reimbursement programs terms

§ 43:33 HIPAA and state data privacy laws terms

§ 43:34 Certification, registration and accreditation terms

§ 43:35 Management agreement terms

- § 43:36 Succession agreement terms
- § 43:37 Business associate agreement terms

## **XI. COMMON BUSINESS MODELS**

- § 43:38 Overview
- § 43:39 Ownership of health care provider franchise by licensed provider
- § 43:40 Ownership over quasi-health care franchise by unlicensed franchisee
- § 43:41 Franchisee as practice manager

## **CHAPTER 44. RETAIL HEALTH CLINICS**

### **I. INTRODUCTION**

- § 44:1 Current trends
- § 44:2 How do RHC's work?
- § 44:3 State regulation of RHC's
- § 44:4 Companies that operate in multiple states

### **II. RETAIL HEALTH CLINIC STRUCTURES**

- § 44:5 Corporate practice of medicine doctrine
- § 44:6 The "Clinic Model"
- § 44:7 The "Professional Entity" Model
- § 44:8 For-profit company (retail health clinic company)

### **III. ANTI-KICKBACK STATUTES**

- § 44:9 Anti-kickback statutes

### **IV. HIPAA COMPLIANCE**

- § 44:10 HIPAA compliance
- § 44:11 Place of service codes
- § 44:12 Retail host store

### **V. THE ROLE OF PHYSICIANS**

- § 44:13 Supervising physicians
- § 44:14 Fee-splitting prohibitions
- § 44:15 Physician self-referral prohibitions
- § 44:16 Physician anti-kickback issues

### **VI. NURSE PRACTITIONERS**

- § 44:17 Authority of nurse practitioners
- § 44:18 Licensing violations
- § 44:19 Professional liability requirements

TABLE OF CONTENTS

**VII. CONCLUSION**

§ 44:20 Conclusion

**CHAPTER 45. RURAL HOSPITALS**

**I. INTRODUCTON**

§ 45:1 Regulatory History

**II. REGULATORY DESIGNATIONS FOR RURAL HOSPITALS**

- § 45:2 Critical access hospitals
- § 45:3 Requirements for CAH designation
- § 45:4 Process for CAH designation
- § 45:5 Special rules/Allowances for CAHs
- § 45:6 Rural referral centers
- § 45:7 Requirements for RRC designation
- § 45:8 Special Rules/Allowances for RRCs
- § 45:9 Medicare-Dependent hospitals
- § 45:10 Requirements for MDH designation
- § 45:11 Special rules/allowances for MDHs
- § 45:12 Sole Community Hospitals
- § 45:13 Requirements for SCH designation
- § 45:14 Special allowances for SCHs
- § 45:15 Medicare low-volume hospitals
- § 45:16 Requirements for MLVH designation
- § 45:17 Special rules/allowances for MLVHs
- § 45:18 Rural health clinics
- § 45:19 Requirements for RHC designation
- § 45:20 Special rules/allowances for RHCs
- § 45:21 Rural emergency hospitals
- § 45:22 Requirements for REH designation
- § 45:23 Special rules/allowances for REHs

**III. PROVIDER SHORTAGE DESIGNATIONS**

- § 45:24 How Shortage Designations are Used
- § 45:25 Types of shortage designations
- § 45:26 Health Professional Shortage Areas (HPSAs)
- § 45:27 Maternity Care Target Areas (MCTAs)
- § 45:28 Medically Underserved Areas (MUAs) and Medically Underserved Populations (MUPs)
- § 45:29 Exceptional MUPS (EMUPS)
- § 45:30 Certified shortage areas for rural health clinics
- § 45:31 Special rules/allowances triggered by shortage designations

- § 45:32 Table 1. Primary Care HPSAs
- § 45:33 Table 2. Mental Health HPSAs
- § 45:34 Table 3. Dental Care HPSAs
- § 45:35 Table 4. MUA/MUP Allowances

#### **IV. RURAL HOSPITAL OUTLOOK AND REGULATORY CHANGES**

- § 45:36 Rural Hospitals Beyond COVID-19

### **CHAPTER 46. TELEMEDICINE**

#### **I. OVERVIEW**

- § 46:1 Introduction

#### **II. WHAT IS TELEMEDICINE?**

- § 46:2 Telemedicine definition
- § 46:3 FSMB Model Policy definition
- § 46:4 Medicare definition
- § 46:5 State law examples
- § 46:6 Need-to-know telemedicine terms

#### **III. WHERE MAY A PROVIDER ENGAGE IN TELEMEDICINE?**

- § 46:7 Introduction
- § 46:8 Licensing and the practice of medicine location
- § 46:9 State law examples
- § 46:10 The Texas Medical Board and the Teladoc case
- § 46:11 Interstate Telemedicine Licensure Compact
- § 46:12 International issues and the GATS National Treatment Provisions

#### **IV. WHO MAY ENGAGE IN TELEMEDICINE?**

- § 46:13 Medicare
- § 46:14 State law examples
- § 46:15 Internet pharmacies and prosecutions
- § 46:16 Online Pharmacy Consumer Protection Act
- § 46:17 State law requirements

#### **V. HOW SHOULD TELEMEDICINE BE PROVIDED?**

- § 46:18 Provider-patient relationship
- § 46:19 Informed consent
- § 46:20 Evaluation and treatment of patient

#### **VI. FRAUD AND ABUSE CONCERNS**

- § 46:21 Anti-Kickback Statute

## TABLE OF CONTENTS

- § 46:22 Safe harbors
- § 46:23 Advisory opinions
- § 46:24 Antikickback Statute case law
- § 46:25 Stark law

## **VII. REIMBURSEMENT FOR TELEMEDICINE**

- § 46:26 Medicare reimbursement
- § 46:27 Medicare site requirements
- § 46:28 Medicare reimbursable services
- § 46:29 Amount of medicare reimbursement
- § 46:30 Commercial payers
- § 46:31 Parity laws

## **VIII. RISK ASSESSMENT**

- § 46:32 Standard of care issues
- § 46:33 Risk of faulty technology
- § 46:34 Joint and several liability
- § 46:35 Patient abandonment
- § 46:36 Security issues

## **IX. THE FUTURE OF TELEMEDICINE**

- § 46:37 Generally

## **CHAPTER 46A. THE COVID-19 CRISIS AND CHANGES TO TELEHEALTH SERVICES**

- § 46A:1 Introduction
- § 46A:2 Covid-19 and the Impact on Telehealth
- § 46A:3 Benefits, Potential Uses and Limitations of Telehealth
- § 46A:4 CMS Telehealth Reimbursement Changes in Response to the COVID-19 Pandemic
- § 46A:5 Other Federal Responses Concerning Telehealth
- § 46A:6 State Laws Incentivizing Telehealth Service
- § 46A:7 Adoption, Implementation, and Utilization of Telehealth Solutions
- § 46A:8 Telehealth from The Investor Side
- § 46A:9 Telehealth Outlook

## **CHAPTER 46B. PRACTICAL CONSIDERATIONS FOR SETTING UP TELEHEALTH SERVICES**

- § 46B:1 Introduction
- § 46B:2 Telehealth definitions
- § 46B:3 Telehealth services: A multidisciplinary approach

- § 46B:4 Where will the provider and patient be located?
- § 46B:5 Will the patients be existing patients, or new patients?
- § 46B:6 How does the provider plan to deliver the telehealth services?
- § 46B:7 Will the provider prescribe medications through the platform?
- § 46B:8 What payor sources do the provider's patients have?
- § 46B:9 What do the provider's professional liability insurance policies say?
- § 46B:10 Practical telehealth resources

## **CHAPTER 47. RESOLVING CODING DISPUTES**

### **I. INTRODUCTION**

- § 47:1 Introduction

### **II. IDENTIFYING CONTROLLING FROM PERSUASIVE STANDARDS**

- § 47:2 Identifying controlling from persuasive standards

### **III. THE FUNDAMENTAL CODING RULE AND ITS IMPLICATIONS**

- § 47:3 The fundamental coding rule and its implications
- § 47:4 HIPAA codeset standard
- § 47:5 Relevant selections from the official comments
- § 47:6 Implications of the codeset rules
- § 47:7 Tips on identifying code selection standards
- § 47:8 Incorporation of CPT®/"AMA Coding Rules"
- § 47:9 Incorporation of "Medicare Coding Rules"
- § 47:10 Incorporation of both or multiple standards
- § 47:11 Incorporation of other standards
- § 47:12 Situations in which there are no express requirements
- § 47:13 Qualifying persuasive standards

### **IV. CONCLUSION**

- § 47:14 Conclusion

## **CHAPTER 48. REAL ESTATE ISSUES**

### **I. INTRODUCTION TO REAL ESTATE ISSUES**

- § 48:1 Introduction

TABLE OF CONTENTS

**II. REAL ESTATE DUE DILIGENCE IN CONNECTION WITH MEGERS, ACQUISITIONS AND AFFILIATIONS**

- § 48:2 Real estate due diligence
- § 48:3 Review of leasing arrangements
- § 48:4 Fraud and abuse compliance
- § 48:5 Lease transfer and consent issues
- § 48:6 Estoppels and non-disturbance protections

**III. REVIEW OF ZONING AND OTHER LAND USE RESTRICTIONS**

- § 48:7 Existing land use restrictions
- § 48:8 Grandfathered non-conforming use
- § 48:9 Subdivision laws and development

**IV. TITLE REVIEW**

- § 48:10 Title review

**V. ENVIRONMENTAL DUE DILIGENCE**

- § 48:11 Environmental due diligence

**VI. BUILDING INSPECTIONS**

- § 48:12 Building inspections

**VII. OTHER DEVELOPMENT CONSIDERATIONS**

- § 48:13 Compliance with existing restrictions
- § 48:14 Imposing CC&Rs on parcels
- § 48:15 Design and construction considerations

**VIII. REAL ESTATE ISSUES FOR TAX-EXEMPT ENTITIES**

- § 48:16 Real estate issues for tax-exempt entities
- § 48:17 Real property tax exemptions
- § 48:18 Hospital facility bond financing/97-13 considerations
- § 48:19 UBIT considerations
- § 48:20 Private Inurement/excess benefits

**CHAPTER 49. BEST PRACTICES IN GOVERNMENT INVESTIGATIONS**

**I. INTRODUCTION**

- § 49:1 Introduction

## **II. INVESTIGATING POTENTIAL HEALTH CARE FRAUD**

- § 49:2 Brief overview of federal regulatory framework of health care fraud
- § 49:3 Anti-Kickback Statute (“AKS”)
- § 49:4 The Stark Law
- § 49:5 The Federal False Claims Act (FCA)

## **III. ORIGIN AND TRAJECTORY OF AN INVESTIGATION**

- § 49:6 Origin and trajectory of an investigation

## **IV. INTERNAL INVESTIGATIONS: IN-HOUSE RESPONSES AND CONSIDERATIONS**

- § 49:7 When should an organization conduct an internal investigation?
- § 49:8 Should an investigation be conducted by inside or outside counsel?

## **V. INVESTIGATIVE TOOLS: SEARCH WARRANTS, SUBPOENAS AND CIDS**

- § 49:9 Search warrants, interviews, undercover operations, subpoenas, & CIDs
- § 49:10 What is the government seeking and why?
- § 49:11 Subpoenas and CIDs
- § 49:12 Marshalling internal assets, gathering data and preparing response to government
- § 49:13 Sarbanes-Oxley
- § 49:14 Yates Memo
- § 49:15 Suggested best practices checklist

## **VI. SELF-DISCLOSURES, OVERPAYMENTS AND FCA CASES**

- § 49:16 AKS violation self disclosures
- § 49:17 Stark law self-disclosures
- § 49:18 Retained overpayments and FCA liability
- § 49:19 Medicare fraud & abuse penalties
- § 49:20 Exclusion
- § 49:21 Civil Monetary Penalties (“CMPs”)

## **VII. CONCLUSION**

- § 49:22 Conclusion

TABLE OF CONTENTS

**CHAPTER 50. ARTIFICIAL INTELLIGENCE  
AND HEALTH CARE**

**I. INTRODUCTION**

§ 50:1 What is artificial intelligence?

**II. AI AND HEALTH CARE**

§ 50:2 Introduction

§ 50:3 Robot-assisted surgery

§ 50:4 Other AI health care applications

**III. OPPORTUNITIES AND CHALLENGES**

§ 50:5 Opportunities and challenges

**CHAPTER 51. MARIJUANA IN THE  
HEALTH CARE SETTING**

§ 51:1 Introduction

§ 51:2 What is Cannabis?

§ 51:3 The Controlled Substances Act

§ 51:4 State regulation of Marijuana

§ 51:5 Federal government response to state legalization of  
Marijuana

§ 51:6 Role of the Centers for Medicare & Medicaid Services  
(CMS)

§ 51:7 Changes in federal enforcement policy

§ 51:8 The Food and Drug Administration (FDA)

§ 51:9 Prospects for change at the federal level

§ 51:10 Medical Marijuana issues in the post-acute care  
industry

§ 51:11 Marijuana and hemp

§ 51:12 Challenges in navigating federal and state laws  
relating to medical Cannabis

§ 51:13 The Impact of federal enforcement on clinical studies

§ 51:14 FDA's position on cannabis for medical use

§ 51:15 Clinical issues relating to senior care

§ 51:16 Medical Marijuana in Skilled Nursing Facilities  
(SNFs)

§ 51:17 Medical Marijuana in Assisted Living Communities  
(ALCs)

§ 51:18 Medical Marijuana in home health care

§ 51:19 Medical Marijuana in hospices

§ 51:20 Protection of post-acute care employees from federal  
prosecution

§ 51:21 Medical Marijuana in hospitals

- § 51:22 Hospital policies on Medical Marijuana use
- § 51:23 Hospital-based clinical studies of medical Cannabis

## **CHAPTER 52. CHILDREN’S HOSPITALS**

### **I. INTRODUCTION**

- § 52:1 Overview of children’s hospitals

### **II. CHILDREN’S HOSPITALS AND PAYERS**

- § 52:2 Payer mix
- § 52:3 Self-pay

### **III. PEDIATRIC SERVICES**

- § 52:4 Specialty services
- § 52:5 Research

### **IV. OPERATIONAL/LEGAL CONSIDERATIONS**

- § 52:6 Overview of considerations
- § 52:7 Consent
- § 52:8 Service-specific consent
- § 52:9 Surrogate decision-makers
- § 52:10 Children in the custody of child protective services agencies: impact on consent and information access

### **V. HIPAA/HITECH AND PERSONAL REPRESENTATIVES OF PATIENT**

- § 52:11 Overview of HIPAA/HITECH
- § 52:12 Child abuse reporting
- § 52:13 Medical malpractice
- § 52:14 Electronic health information considerations

### **VI. MEDICAL CARE FOR MINORS**

- § 52:15 Pediatric treatments
- § 52:16 End of life and withdrawal of life-sustaining treatment
- § 52:17 Refusal of care

### **VII. STRATEGIC CONSIDERATIONS**

- § 52:18 Overview of strategic considerations
- § 52:19 Academic affiliation
- § 52:20 Physician Alignment
- § 52:21 Adult provider partners
- § 52:22 Community Outreach

TABLE OF CONTENTS

§ 52:23 Collaboration among children's hospitals

**VIII. FINANCIAL CONSIDERATIONS: THE IMPACT  
OF MEDICAID CUTS, COMMERCIAL  
INSURANCE, AND SELF-PAY**

§ 52:24 Overview of financial considerations

**APPENDICES**

Appendix A. Year in Review (Case Law) June 2023-May 2024

Appendix B. Contemporary Issues in Health Law 2023-2024

# **Table of Contents**

## **APPENDICES (CONTINUED)**

Appendix C. Forms, Policies and Procedures<sup>Ⓢ</sup>

Appendix D. Health Law Glossary and Acronyms

**Table of Laws and Rules**

**Table of Cases**

**Index**